[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2416
1. Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG: Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Jan;30(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Adult survivors of childhood acute lymphoblastic leukemia (ALL) have an earlier than expected mortality from cardiovascular disease.
  • This study examined endothelial function in 75 young (age 30.2+/-7.1 y) adult survivors of childhood ALL who received chemotherapy without cranial radiation (n=25) or chemotherapy combined with cranial radiation (n=50) compared with a healthy control group of similar sex, age, and weight (n=59).
  • CONCLUSIONS: These data suggest that young adults treated for ALL during childhood are at risk for impaired FMD regardless of whether or not they received cranial irradiation.
  • The extent to which this mechanism relates to early development of cardiovascular disease in long-term childhood ALL survivors remains to be determined.
  • [MeSH-major] Brachial Artery / physiopathology. Endothelium, Vascular / physiopathology. Nitroglycerin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Vasodilation / drug effects. Vasodilator Agents / administration & dosage
  • [MeSH-minor] Adult. Child. Child, Preschool. Cranial Irradiation. Female. Follow-Up Studies. Humans. Male. Sex Factors. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176175.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; G59M7S0WS3 / Nitroglycerin
  •  go-up   go-down


2. Mann G, Cazzaniga G, van der Velden VH, Flohr T, Csinady E, Paganin M, Schrauder A, Dohnal AM, Schrappe M, Biondi A, Gadner H, van Dongen JJ, Panzer-Grümayer ER: Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease? Leukemia; 2007 Apr;21(4):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease?
  • The t(4;11)-positive acute lymphoblastic leukemia (ALL) is a rare disease in children above the age of 1 year.
  • We studied the clinical and biological characteristics in 32 consecutively diagnosed childhood cases (median age 10.0 years, range 1.0-17.1 years).
  • /2.3 gene segment, an unusual combination among t(4;11)-negative B-cell precursor ALL.
  • Our data are in line with transformation of a precursor cell at an early stage of B-cell development but retaining the potential to differentiate to the pre-B cell stage in vivo.
  • Although a distinct difference between infant and older childhood cases with t(4;11) became evident, no age-related biological features were found within the childhood age group.
  • In contrast to infants with t(4;11)-positive ALL, childhood cases had a relatively low cumulative incidence of relapse of 25% at 3.5 years with BFM-based high-risk protocols.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287854.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


3. Ecklund EH, Cadge W, Gage EA, Catlin EA: The religious and spiritual beliefs and practices of academic pediatric oncologists in the United States. J Pediatr Hematol Oncol; 2007 Nov;29(11):736-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The religious and spiritual beliefs and practices of academic pediatric oncologists in the United States.
  • This study evaluates religious and spiritual beliefs and practices among pediatric oncology faculty and compares their religiosity and spirituality to the general public.
  • METHODS: Information was gathered from a sampling frame of all pediatric oncology faculty working in 13 US News and World Report's "honor role" hospitals.
  • RESULTS: Eighty-five percent of pediatric oncology faculty described themselves as spiritual.
  • Twenty-seven percent of pediatric oncologists believed in God with no doubts.
  • CONCLUSIONS: Although many have no traditional religious identity, large fractions of pediatric oncology faculty described themselves as spiritual.
  • This may have implications for the education of pediatric oncologists and the spiritual care of seriously ill children and their families.

  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Nov;29(11):733-5 [17984689.001]
  • (PMID = 17984690.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Tolar J, Bostrom BC, La MK, Sather HN: Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922. Pediatr Blood Cancer; 2005 Jul;45(1):5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
  • PURPOSE: To compare outcomes of patients with NCI standard risk acute lymphoblastic leukemia (ALL) who relapsed after being randomized to receive either oral or intravenous 6-mercaptopurine (6MP) in the Children's Cancer Group study CCG 1922.
  • CONCLUSION: Treatment with intravenous 6MP during a brief period of total therapy had a significant negative impact on the prognosis in childhood ALL even though oral 6MP was used during maintenance.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Humans. Infant. Infusions, Intravenous. Life Tables. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 May 1;46(5):660-1 [16276523.001]
  • [CommentIn] Pediatr Blood Cancer. 2005 Jul;45(1):2-4 [15706584.001]
  • (PMID = 15481062.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-13539
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


5. Choit RL, Jamieson DH, Reilly CW: Os odontoideum: a significant radiographic finding. Pediatr Radiol; 2005 Aug;35(8):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Os odontoideum can lead to instability of the atlantoaxial joint and places the spinal cord at significant risk for acute catastrophic events after minor trauma or chronic neurological change.
  • We present two cases of os odontoideum in pediatric patients that were not appreciated at earlier remote imaging but were, in retrospect, detectable.
  • One patient presented with an acute spinal cord injury.
  • Incorporating assessment of dens integrity into the evaluation algorithm for all pediatric cervical spine studies should lead to early detection of os odontoideum lesions and allow referral to appropriate clinical spinal services for evaluation, surveillance and possible surgery to prevent future complications.
  • [MeSH-minor] Adolescent. Atlanto-Axial Joint / diagnostic imaging. Atlanto-Axial Joint / pathology. Child. Diagnosis, Differential. Female. Humans. Joint Instability / diagnosis. Magnetic Resonance Imaging. Male. Radiography. Spinal Cord Injuries / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Orthop. 1990 Sep-Oct;10 (5):602-6 [2144298.001]
  • [Cites] J Bone Joint Surg Am. 1969 Jul;51(5):965-72 [5793853.001]
  • [Cites] J Bone Joint Surg Am. 1963 Oct;45:1459-71 [14069784.001]
  • [Cites] Spine (Phila Pa 1976). 2000 May 1;25(9):1178-81 [10788864.001]
  • [Cites] Ann Emerg Med. 1989 Dec;18(12 ):1358-61 [2589705.001]
  • [Cites] J Bone Joint Surg Am. 1974 Jan;56(1):187-90 [4812163.001]
  • [Cites] J Pediatr Orthop. 1998 Nov-Dec;18(6):815-9 [9821143.001]
  • [Cites] Acta Orthop Scand. 1983 Feb;54(1):113-8 [6829275.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1990 Aug;98 (2):89-93 [2378323.001]
  • [Cites] J Bone Joint Surg Am. 1976 Apr;58(3):413-4 [1262377.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1987 May;91(5):414-26 [3554978.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Nov 1;25(21):2777-83 [11064523.001]
  • [Cites] Eur Spine J. 2004 Jul;13(4):295-300 [15232724.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 2003 Aug;124(2):184-9 [12923515.001]
  • [Cites] J Bone Joint Surg Am. 1965 Oct;47(7):1295-309 [5837630.001]
  • [Cites] Am J Forensic Med Pathol. 1990 Sep;11(3):252-6 [2220713.001]
  • [Cites] Radiology. 1952 Nov;59(5):712-9 [12994006.001]
  • [Cites] J Bone Joint Surg Am. 1980 Apr;62(3):376-83 [7364809.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1999 Nov;116(5):572-7 [10547519.001]
  • [Cites] J Pediatr Orthop. 1991 Mar-Apr;11(2):222-5 [2010525.001]
  • [Cites] J Bone Joint Surg Am. 1991 Dec;73(10 ):1547-54 [1836215.001]
  • [Cites] Pediatr Radiol. 2002 Jan;32(1):34-40 [11819061.001]
  • (PMID = 15864578.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Feller M, Adam M, Zwahlen M, Brazzola P, Niggli F, Kuehni C, Swiss Pediatric Oncology Group (SPOG), Swiss National Cohort (SNC): Family characteristics as risk factors for childhood acute lymphoblastic leukemia: a population-based case-control study. PLoS One; 2010;5(10)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family characteristics as risk factors for childhood acute lymphoblastic leukemia: a population-based case-control study.
  • BACKGROUND: To date, few risk factors for childhood acute lymphoblastic leukemia (ALL) have been confirmed and the scientific literature is full of controversial "evidence."
  • We examined if family characteristics, particularly maternal and paternal age and number of older siblings, were risk factors for childhood acute lymphoblastic leukemia (ALL).
  • METHODOLOGY/PRINCIPAL FINDINGS: In this population-based nationwide matched case-control study, patients 0-14 years of age with ALL diagnosed 1991-2006 and registered in the Swiss Childhood Cancer Registry were linked with their census records of 1990 and 2000.
  • [MeSH-major] Family. Population Surveillance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Female. Humans. Infant. Male. Registries. Risk Factors. Switzerland / epidemiology


7. Spasova MI, Stoyanova AA, Moumdjiev IN, Dimitrov HK: Childhood acute lymphoblastic leukemia presenting with osteoarticular syndrome--characteristics and prognosis. Folia Med (Plovdiv); 2009 Jan-Mar;51(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukemia presenting with osteoarticular syndrome--characteristics and prognosis.
  • Children with leukemia often present with osteoarticular syndrome as a first complaint thus mimicking juvenile idiopathic arthritis.
  • The objective of the present study was to determine the frequency of osteoarticular syndrome at the onset of acute lymphoblastic leukemia in childhood, the clinical and laboratory specificity of such patients and the prognostic value of osteoarticular syndrome as an initial symptom.
  • PATIENTS AND METHODS: We studied 60 children with acute lymphoblastic leukemia at a mean age of 5 +/- 0.5 years between February 2002 and October 2007.
  • RESULTS: Osteoarticular syndrome was present as an initial symptom of leukemia in 18 (30.5%) patients.
  • Event-free survival in patients with osteoarticular syndrome is comparable to that of the remaining group of acute lymphoblastic leukemia patients.
  • [MeSH-major] Arthritis, Juvenile / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Bulgaria / epidemiology. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Joints / pathology. Joints / physiopathology. Leukocyte Count. Male. Prognosis. Survival Rate


8. He GS, Zhang XH, Yao L, Zhang R, Chen ZX, Wu DP, Sun AN, Jin ZM, Qiu HY, Hu XH: [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):675-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
  • OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).
  • CONCLUSION: t(1;19)E2A-PBX1(+) can be implicated in adult T-ALL, besides childhood B-ALL.
  • [MeSH-major] Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954663.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


9. Hamouda F, El-Sissy AH, Radwan AK, Hussein H, Gadallah FH, Al-Sharkawy N, Sedhom E, Ebeid E, Salem SI: Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt. J Egypt Natl Canc Inst; 2007 Jun;19(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
  • [MeSH-major] Antigens, Neoplasm / analysis. Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Case-Control Studies. Child. Chromosome Banding. Diploidy. Egypt. Female. Flow Cytometry. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Retrospective Studies. Universities


10. Yeoh AE, Lu Y, Chan JY, Chan YH, Ariffin H, Kham SK, Quah TC: Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group. Leuk Res; 2010 Mar;34(3):276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group.
  • To study genetic epidemiology of childhood acute lymphoblastic leukemia (ALL) in the Chinese and Malays, we investigated 10 polymorphisms encoding carcinogen- or folate-metabolism and transport.
  • [MeSH-major] Genetic Predisposition to Disease. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Asian Continental Ancestry Group. Child. Child, Preschool. Female. Genotype. Humans. Infant. Infant, Newborn. Malaysia / epidemiology. Male. Polymorphism, Single Nucleotide. Sex Characteristics. Singapore / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • [CommentIn] Leuk Res. 2010 Mar;34(3):269-71 [19716175.001]
  • (PMID = 19651439.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Bury J, Hurt C, Roy A, Cheesman L, Bradburn M, Cross S, Fox J, Saha V: LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia. Br J Haematol; 2005 Jun;129(6):746-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia.
  • Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia.
  • A web-based decision-support system (Leukaemia Intervention Scheduling and Advice, 'LISA') was designed to facilitate access to FBC information across geographical locations and to assist with dosage adjustments.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Clinical Trials as Topic / methods. Decision Support Systems, Clinical. Internet. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Clinical Protocols. Cross-Over Studies. Drug Administration Schedule. Drug Therapy, Computer-Assisted / methods. Guideline Adherence. Humans

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953000.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Tham EH, Tay SK, Low PS: Factors predictive of outcome in childhood stroke in an Asian population. Ann Acad Med Singapore; 2009 Oct;38(10):876-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of outcome in childhood stroke in an Asian population.
  • The aim of this study was to evaluate the epidemiology of childhood stroke in a tertiary paediatric unit in Singapore and to assess factors influencing outcome in these children.
  • MATERIALS AND METHODS: A retrospective case-note review of all childhood strokes presenting to the Children's Medical Institute (CMI) at the National University Hospital (NUH), Singapore between October 1999 and May 2006.
  • [MeSH-minor] Adolescent. Age Factors. Asian Continental Ancestry Group. Brain Ischemia / epidemiology. Brain Ischemia / etiology. Brain Ischemia / rehabilitation. Cerebral Hemorrhage / etiology. Child. Child, Preschool. Developmental Disabilities / etiology. Female. Humans. Infant. Intracranial Arteriovenous Malformations / complications. Length of Stay / statistics & numerical data. Male. Neuropsychological Tests. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Singapore / epidemiology. Treatment Outcome. Vascular Diseases / complications

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890579.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


13. Jain N, Brouwers P, Okcu MF, Cirino PT, Krull KR: Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia. Cancer; 2009 Sep 15;115(18):4238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Neurocognitive problems are a frequent outcome of chemotherapy for pediatric leukemia, although individual differences exist in patient outcome.
  • The purpose of this study was to evaluate the pattern of attention problems in male and female long-term survivors of pediatric acute lymphoblastic leukemia (ALL).
  • CONCLUSIONS: The results of this study suggest that children diagnosed with and treated for pediatric ALL perform poorly on select measures of attention and executive control, and that this performance is influenced by sex and treatment intensity.
  • [MeSH-major] Attention. Cognition Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sex Characteristics. Survivors / psychology
  • [MeSH-minor] Age of Onset. Child. Female. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19536898.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hernández Sánchez JE, Gómez Vegas A, Blázquez Izquierdo J, Grimalt Alvarez J, Pérez Contín MJ, Rabadán Marina M, San José Manso L, Alonso Prieto M, Pérez Romero N, Silmi Moyano A: [En bloc transplantation of pediatric donor kidneys to adult receptors]. Arch Esp Urol; 2007 Mar;60(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [En bloc transplantation of pediatric donor kidneys to adult receptors].
  • [Transliterated title] Trasplante en bloque de riñones procedentes de donantes pediatricos en receptores adultos.
  • OBJECTIVES: Analysis of all pediatric donor en bloc transplants to adult receptors performed in our department.
  • RESULTS: There were significant differences in terms of nonfunctioning kidneys and delayed graft function, more frequent in pediatric en bloc and adult transplants, respectively.
  • Pediatric kidneys provided better renal function and less proteinuria.
  • One and five-year graft survivals were 83.56% and 8 1.47% for pediatric donor kidneys, and 91.50% and 86.99% for adult donor kidneys.
  • CONCLUSIONS: Pediatric donor en bloc transplants have an excellent survival and function in the middle and long-term.
  • Vascular complications are the main cause of pediatric donor graft loss.
  • The adoption of a pediatric donor en bloc transplant program increases the transplant activity.
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Female. Graft Survival. Humans. Immunosuppressive Agents / therapeutic use. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Spain. Survival Analysis. Tissue Donors. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484481.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


15. Kamiya H, Nakano T, Inoue M, Kamiya H, Abd TT, Patel M, Orenstein WA, Parashar UD: A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus. J Infect Dis; 2009 Nov 1;200 Suppl 1:S140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus.
  • METHODS: To describe the epidemiology of severe rotavirus disease among Japanese children aged <5 years, we examined retrospective demographic, clinical, and laboratory data from the period 2003-2007 for children hospitalized with acute gastroenteritis (AGE) at 2 sentinel hospitals in Japan.
  • RESULTS: At each of the 2 hospitals, 17%-21% of all pediatric hospitalizations were for AGE.
  • [MeSH-minor] Acute Disease. Humans. Japan / epidemiology. Retrospective Studies. Seasons

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • MedlinePlus Health Information. consumer health - Rotavirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817592.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Yanke BV, Horowitz M: Safety of the Veress needle in pediatric laparoscopy. J Endourol; 2007 Jul;21(7):695-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of the Veress needle in pediatric laparoscopy.
  • PURPOSE: To better establish the complication rate with the Veress needle technique for establishing a pneumoperitoneum in pediatric laparoscopy.
  • PATIENTS AND METHODS: We reviewed all pediatric laparoscopy cases performed by a single surgeon from 1996 to 2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705752.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Stanulla M, Schünemann HJ: Thioguanine versus mercaptopurine in childhood ALL. Lancet; 2006 Oct 14;368(9544):1304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thioguanine versus mercaptopurine in childhood ALL.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use
  • [MeSH-minor] Child. Disease-Free Survival. Humans. Randomized Controlled Trials as Topic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • (PMID = 17046444.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


18. Xu W, Tang Y, Song H, Shi S, Yang S: Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol; 2007 Oct;29(10):688-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
  • OBJECTIVES: The aim of this study was to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities.
  • PATIENTS AND METHODS: A total of 121 children with acute lymphoblastic leukemia on HDMTX therapy were enrolled into this study.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Interactions. Female. Fluid Therapy. Humans. Infant. Infusions, Intravenous. Liver / drug effects. Liver / pathology. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921849.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Sitaresmi MN, Mostert S, Gundy CM, Sutaryo, Veerman AJ: Health-care providers' compliance with childhood acute lymphoblastic leukemia protocol in Indonesia. Pediatr Blood Cancer; 2008 Dec;51(6):732-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-care providers' compliance with childhood acute lymphoblastic leukemia protocol in Indonesia.
  • BACKGROUND: Non-compliance with childhood acute lymphoblastic leukemia (ALL) protocol is an important determinant of poor treatment outcome.
  • Our study examines the accuracy of leukemia risk classification and attitude of HCP toward protocol compliance in Indonesia.
  • CONCLUSIONS: Our study shows that HCP should improve their knowledge and assessment of childhood ALL risk classification, especially lymphoblast count on day 8 of chemotherapy.
  • Proper risk classification and subsequent correct treatment may enable more children to be cured of leukemia.
  • [MeSH-major] Delivery of Health Care / standards. Guideline Adherence / standards. Health Personnel / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Child. Child, Preschool. Cross-Sectional Studies. Humans. Indonesia / epidemiology. Infant. Prognosis. Retrospective Studies. Risk Factors. Surveys and Questionnaires


20. Yeung J, Kempski H, Neat M, Bailey S, Smith O, Brady HJ: Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells. Haematologica; 2006 Mar;91(3):422-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the first report to comprehensively characterize the E2A-HLF fusion generated from the t(17;19)(q22;p13) translocation in childhood B-lineage acute lymphoblastic leukemia.
  • [MeSH-minor] Adolescent. Child, Preschool. Cytogenetic Analysis / methods. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531271.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / E2a-Hlf fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


21. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood; 2005 Sep 1;106(5):1817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
  • Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis.
  • To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).
  • In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Caspases / metabolism. Drug Resistance, Neoplasm / physiology. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Apoptosis / physiology. Caspase 2. Cell Line, Tumor. Child. Drug Screening Assays, Antitumor. Gene Expression Regulation, Enzymologic. Humans. RNA, Messenger / genetics. RNA, Messenger / physiology


22. Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I: WT1 protein expression in childhood acute leukemia. Am J Hematol; 2008 May;83(5):382-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 protein expression in childhood acute leukemia.
  • In patients with acute leukemia, Wilms' tumor gene 1 (WT1) has been used as a target for the detection of minimal residual disease (MRD) by PCR techniques.
  • To determine the relation between expression of WT1 transcripts and of the encoded protein, we examined leukemic cell lines and primary childhood leukemia samples using both real-time quantitative PCR (RQ-PCR) and flow cytometry.
  • By contrast, 40 primary samples of acute lymphoblastic leukemia (ALL; B-ALL, n = 15 and T-ALL, n = 10) and acute myeloid leukemia (n = 15) expressed low levels of WT1 protein.
  • RQ-PCR detected WT1 transcript levels in the same range as reported in earlier studies in childhood acute leukemia.
  • (ii) WT1 is not a suitable marker for flow cytometric MRD detection in childhood acute leukemia.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Blood Cells / metabolism. Bone Marrow Cells / metabolism. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / metabolism. Child. Child, Preschool. Female. Flow Cytometry. Genes, Wilms Tumor. Humans. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18161786.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  •  go-up   go-down


23. Jeha S: New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):76-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic strategies in acute lymphoblastic leukemia.
  • While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Drug Delivery Systems. Folic Acid / metabolism. Humans. Nucleosides / therapeutic use. Protein Kinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100370.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Nucleosides; 0 / Protein Kinase Inhibitors; 935E97BOY8 / Folic Acid
  • [Number-of-references] 167
  •  go-up   go-down


24. Kheifets L, Swanson J, Greenland S: Childhood leukemia, electric and magnetic fields, and temporal trends. Bioelectromagnetics; 2006 Oct;27(7):545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia, electric and magnetic fields, and temporal trends.
  • During the past 25 years concern has been raised about the possible health effects of extremely low frequency (ELF) electric and magnetic fields (EMFs), particularly regarding childhood leukemia.
  • Comparison of changes in electricity consumption (a surrogate for exposure) to changes in childhood-leukemia rates, known as ecologic correlation, have been used to argue both for and against the association between magnetic fields and childhood leukemia.
  • We first examine separately the evidence on trends in exposure to EMFs and on trends in leukemia rates, and then compare the two.
  • [MeSH-major] Electricity / adverse effects. Electromagnetic Fields / adverse effects. Environmental Exposure. Leukemia, Radiation-Induced
  • [MeSH-minor] Acute Disease / epidemiology. Child. Child, Preschool. Great Britain / epidemiology. Humans. Incidence. Leukemia, Myeloid / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724316.001).
  • [ISSN] 0197-8462
  • [Journal-full-title] Bioelectromagnetics
  • [ISO-abbreviation] Bioelectromagnetics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kiss F, Buslig J, Szegedi I, Scholtz B, Kappelmayer J, Kiss C: Early relapse after rituximab chemoimmunotherapy. Pediatr Blood Cancer; 2008 Feb;50(2):372-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In relapsed/refractory childhood acute lymphoblastic leukemia (ALL) of the B-cell lineage rituximab, a monoclonal anti-CD20 antibody was used successfully in some cases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973316.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


26. Prucker C, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, Fink FM, Meister B, Schmitt K, Haas OA, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group. Leukemia; 2009 Jul;23(7):1264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.
  • In the management of the childhood acute lymphoblastic leukemia (ALL), 5% of failures are due to induction death and treatment-related deaths in first complete remission.
  • [MeSH-major] Antineoplastic Agents / toxicity. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Remission Induction
  • [MeSH-minor] Cause of Death. Child. Female. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212332.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Investigator] Ausserer B; Busch U; Müller G; Kurz R; Urban Ch; Berger H; Fink FM; Meister B; Kaulfersch W; Messner H; Mutz I; Stöllinger O; Tulzer W; Schmitt K; Ebetsberger T; Grienberger H; Jones N; Jones R; Rücke J; Haas H; Ploier R; Gadner H; Krepler P; Mann G; Pichler E; Jürgenssen O; Slavc I; Höcker P; Knapp W; Pickl WF; Haas OA; Lion T; Kärcher KH; Hawlicek R; Pötter R; Dieckmann K
  •  go-up   go-down


27. Bechtold S, Putzker S, Birnbaum J, Schwarz HP, Netz H, Dalla Pozza R: Impaired bone geometry after heart and heart-lung transplantation in childhood. Transplantation; 2010 Nov 15;90(9):1006-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired bone geometry after heart and heart-lung transplantation in childhood.
  • BACKGROUND: Impaired bone health has been advocated after solid organ transplantation in adult and pediatric patients.
  • CONCLUSION: After heart transplantation and heart-lung transplantation in childhood, all our patients showed altered bone geometry and low muscle CSA.
  • [MeSH-minor] Adolescent. Adult. Body Mass Index. Child. Diaphyses / anatomy & histology. Female. Forearm. Glucocorticoids / therapeutic use. Humans. Infant. Male. Radius / anatomy & histology


28. Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP: Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol; 2009 Dec 10;27(35):5986-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
  • PURPOSE: For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cognition / drug effects. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Attention / drug effects. Child. Child, Preschool. Cross-Sectional Studies. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Injections, Spinal. Intelligence Tests. Linear Models. Male. Memory / drug effects. Neuropsychological Tests. Psychomotor Performance / drug effects. Time Factors. Treatment Outcome. United States


29. Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M: DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res; 2009 Nov 15;15(22):6931-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.
  • PURPOSE: Dihydrofolate reductase (DHFR) is the major target of methotrexate, a key component in childhood acute lymphoblastic leukemia (ALL) treatment.
  • [MeSH-major] DNA / genetics. Genetic Variation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tetrahydrofolate Dehydrogenase / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Child. Cohort Studies. Female. Haplotypes. Humans. Male. Methotrexate / pharmacology. Middle Aged. Pharmacogenetics. Polymorphism, Genetic. Promoter Regions, Genetic


30. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, Friedman DL: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant; 2010 Dec;16(12):1674-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) may face an increased risk of metabolic and cardiovascular late effects.
  • To determine the prevalence of and risk factors for adverse cardiometabolic traits in a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell transplantation (HCT) in this cross-sectional pilot study.
  • In summary, pediatric ALL survivors exposed to TBI-based HCT as well as to any cranial radiation may manifest cardiometabolic traits at an early age and should be screened accordingly.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1521-5 [15585763.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Cardiovasc Res. 2007 Apr 1;74(1):11-8 [17140553.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3463-71 [17664354.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):160-4 [18206681.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):177-84 [18206686.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):185-90 [18206687.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):797-804 [18195686.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Jun;21(2):129-38 [18503981.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):11-26 [18430191.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Nov;69(5):819-27 [18429947.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5537-43 [18809605.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):49-54 [18724397.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3698-704 [19564534.001]
  • [Cites] PLoS Genet. 2009 Dec;5(12):e1000768 [20011104.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81 [20056636.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24 [19961945.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):993-7 [11041401.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2184-91 [11481415.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90 [14767193.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):439-44 [15480363.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Can J Public Health. 1986 Sep-Oct;77(5):359-62 [3791117.001]
  • [Cites] Am J Epidemiol. 1996 Jun 15;143(12):1219-28 [8651220.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1650-6 [9614255.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1376-83 [15548978.001]
  • (PMID = 20685399.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024975-01; United States / NCRR NIH HHS / RR / UL1 RR025014-01; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; None / None / / UL1 RR025014-01; United States / NCRR NIH HHS / RR / UL1RR025014; United States / NCRR NIH HHS / RR / UL1RR024975; United States / NCRR NIH HHS / RR / UL1 RR025014; United States / NCRR NIH HHS / RR / UL1 RR024975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS211258; NLM/ PMC2975816
  •  go-up   go-down


31. Tofil NM, Lee White M, Manzella B, McGill D, Zinkan L: Initiation of a pediatric mock code program at a children's hospital. Med Teach; 2009 Jun;31(6):e241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initiation of a pediatric mock code program at a children's hospital.
  • BACKGROUND: Pediatric cardiopulmonary arrests are rare.
  • AIM: The goal was to improve medical caregivers' skills in pediatric resuscitation.
  • METHODS: All pediatric and internal medicine/pediatric (med/peds) residents were anonymously surveyed pre- and post-intervention about confidence level about codes and code skills.
  • Statistical comparisons were made between each resident pre- and post-survey, graduating third-year residents (PGY3s) prior to intervention versus PGY3s with mock codes and pediatric versus med/peds residents.
  • Med/peds residents were significantly more confident in their skills than pediatric residents both pre- (p = 0.041) and post-intervention (p = 0.016).
  • CONCLUSIONS: Pediatric mock codes can improve resident confidence and self-assessment of their resuscitation skills.
  • [MeSH-minor] Adult. Child. Child, Preschool. Data Collection. Educational Status. Female. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Internal Medicine / education. Male. Models, Educational. Patient Care Team. Pediatrics / education. Self-Assessment

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - CPR.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811155.001).
  • [ISSN] 1466-187X
  • [Journal-full-title] Medical teacher
  • [ISO-abbreviation] Med Teach
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Mahle WT: Cardiac retransplantation in children. Pediatr Transplant; 2008 May;12(3):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To discuss the indications for and outcomes of cardiac retransplantation in childhood.
  • The major challenge of pediatric heart transplantation is graft failure.
  • Retransplantation may be considered in children or young adults who develop graft failure following pediatric heart transplantation.
  • Retransplantation now accounts for 7% of all pediatric transplants.
  • Novel therapies to extend the life of the primary graft and to stratify those at risk of severe graft dysfunction will improve the allocation of scarce organs for pediatric patients who might be candidates for cardiac retransplantation.
  • [MeSH-minor] Child. Heart Diseases / complications. Heart Diseases / therapy. Humans. Immunosuppressive Agents / therapeutic use. Kidney Diseases / complications. Prognosis. Reoperation / methods. Reoperation / statistics & numerical data. Risk. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18435605.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


33. Sawczyn KK, Quinones R, Malcolm J, Foreman N, Garrington T, Gore L, Gao D, Giller R: Cord blood transplant in childhood ALL. Pediatr Blood Cancer; 2005 Dec;45(7):964-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cord blood transplant in childhood ALL.
  • BACKGROUND: Optimal therapy for high risk and relapsed acute lymphoblastic leukemia (ALL) remains uncertain.
  • Acute GVHD developed in 14/24 evaluable patients, reaching grade III-IV in 7 patients.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Histocompatibility Testing. Humans. Infant. Male. Multivariate Analysis. Recurrence. Retrospective Studies. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2005 Dec;45(7):874-5 [16187299.001]
  • (PMID = 15929135.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. McGuire JJ, Haile WH, Yeh CC: 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res; 2006 Apr 1;66(7):3836-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that [(3)H]MTX influx in CCRF-CEM human childhood T-leukemia cells is potentiated up to 6-fold by exogenous 5-amino-4-imidazolecarboxamide riboside (AICAr) in a AICAr and MTX concentration-dependent manner.
  • Acute folate deficiency or incubation of CCRF-CEM with AICAr-related metabolites (e.g., adenosine) does not initiate potentiation.
  • [MeSH-major] Aminoimidazole Carboxamide / analogs & derivatives. Leukemia, T-Cell / metabolism. Membrane Transport Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Ribonucleotides / pharmacology
  • [MeSH-minor] Biological Transport / drug effects. Cell Line, Tumor. Child. Dose-Response Relationship, Drug. Drug Synergism. Folic Acid Antagonists / metabolism. Folic Acid Antagonists / pharmacokinetics. Humans. Kinetics. Methotrexate / analogs & derivatives. Methotrexate / metabolism. Methotrexate / pharmacokinetics. Phosphoribosylglycinamide Formyltransferase / antagonists & inhibitors. Phosphoribosylglycinamide Formyltransferase / metabolism. Polyglutamic Acid / analogs & derivatives. Polyglutamic Acid / biosynthesis. Polyglutamic Acid / pharmacokinetics. Reduced Folate Carrier Protein. Subcellular Fractions. Temperature. Thymidylate Synthase / antagonists & inhibitors. Thymidylate Synthase / metabolism. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585211.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056; United States / NCI NIH HHS / CA / CA 43500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / Ribonucleotides; 0 / SLC19A1 protein, human; 10028-17-8 / Tritium; 25513-46-6 / Polyglutamic Acid; 360-97-4 / Aminoimidazole Carboxamide; 82334-40-5 / methotrexate polyglutamate; EC 2.1.1.45 / Thymidylate Synthase; EC 2.1.2.2 / Phosphoribosylglycinamide Formyltransferase; F0X88YW0YK / AICA ribonucleotide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Ma G, Chong L, Li XC, Khan IA, Walker LA, Khan SI: Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B. J Cancer Res Clin Oncol; 2010 Sep;136(9):1333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B.
  • PURPOSE: The leukemias account for the largest number of cases of childhood cancer and remain the primary cause of cancer-related mortality among children in the United States.
  • In this study, the effects of pseudolaric acid B (PAB) on three human leukemia cell lines, acute promyelocytic leukemia HL-60 cells, acute lymphoblastic leukemia CCRF-CEM cells, and human chronic myeloid leukemia blast-phase K562 cells were investigated in vitro, compared to normal human peripheral blood mononuclear cells (PBMC).
  • RESULTS: Pseudolaric acid B selectively inhibited the growth of human leukemia HL-60, CCRF-CEM and K562 cells, but not normal PBMC.
  • CONCLUSIONS: This study indicates that PAB has a potential for use against leukemia and its effects might be mediated by inhibiting tubulin polymerization, preventing cell division and activating caspase-3, which leads to apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Diterpenes / pharmacology. Leukemia / drug therapy. Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Pseudolaric Acid B .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Ther. 1988;37(3):425-61 [3290912.001]
  • [Cites] FEBS Lett. 1992 Jul 27;307(1):122-7 [1639187.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17 [12678749.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6002-11 [16115945.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jun;46(6):1785-92 [12019091.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2212-22 [2009540.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2005 Jan;30(1):55-7 [15714803.001]
  • [Cites] Bioorg Med Chem. 2003 Oct 15;11(21):4577-84 [14527554.001]
  • [Cites] Planta Med. 1990 Aug;56(4):383-5 [2236294.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Exp Mol Med. 2004 Dec 31;36(6):551-6 [15665588.001]
  • [Cites] Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):60-2 [2403017.001]
  • [Cites] Med Res Rev. 1997 Jul;17(4):367-425 [9211397.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Planta Med. 1983 Jan;47(1):35-8 [17405089.001]
  • [Cites] Lipids. 2005 Mar;40(3):303-8 [15957257.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):35-43 [17149609.001]
  • [Cites] Am Fam Physician. 2008 Feb 1;77(3):311-9 [18297955.001]
  • [Cites] Toxicology. 2002 Jun 14;175(1-3):123-42 [12049842.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):400-7 [18536580.001]
  • [Cites] Curr Pharm Des. 1998 Jun;4(3):219-48 [10197041.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] World J Gastroenterol. 2005 Dec 28;11(48):7555-9 [16437677.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] J Nat Prod. 1999 May;62(5):767-9 [10346966.001]
  • [Cites] Arch Pharm Res. 2005 Jan;28(1):68-72 [15742811.001]
  • [Cites] J Nat Prod. 1997 Jan;60(1):52-60 [9014353.001]
  • [Cites] J Nat Prod. 1995 Jan;58(1):57-67 [7760078.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • (PMID = 20140742.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diterpenes; 82508-31-4 / pseudolaric acid B
  •  go-up   go-down


36. Rothstein DH, Voss SD, Isakoff M, Puder M: Thymoma in a child: case report and review of the literature. Pediatr Surg Int; 2005 Jul;21(7):548-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma in a child: case report and review of the literature.
  • Thymic lesions comprise approximately 2-3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
  • Thymomas, which represent less than 1% of all mediastinal tumors, are rare mediastinal tumors in the pediatric population.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 May;69(5):1550-5 [10881840.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):30-3 [2049749.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):219-24 [8757387.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S95-S102 [12376603.001]
  • [Cites] J Pediatr Surg. 1990 Nov;25(11):1143-6 [2273428.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1994 Oct;6(4):235-9 [7803582.001]
  • [Cites] Cancer. 1994 May 15;73(10):2491-8 [8174044.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Jul-Sep;9(3):261-8 [1525005.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1405-13 [11920495.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 May;89(3):223-6 [6947681.001]
  • [Cites] Pediatr Radiol. 1993;23 (2):124-6 [8516035.001]
  • [Cites] J Pediatr Surg. 1982 Oct;17(5):512-20 [7175638.001]
  • [Cites] Ann Thorac Surg. 1978 Feb;25(2):91-8 [626543.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2280-9 [10561285.001]
  • [Cites] Thorax. 1975 Feb;30(1):19-25 [1124527.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2485-92 [7296496.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):203-7 [11465180.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):624-32 [11857293.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):562-72; discussion 572-4 [10522726.001]
  • [Cites] Ann Thorac Surg. 1991 Mar;51(3):378-84; discussion 385-6 [1998414.001]
  • (PMID = 15926048.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


37. Richards NG, Kilberg MS: Asparagine synthetase chemotherapy. Annu Rev Biochem; 2006;75:629-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modern clinical treatments of childhood acute lymphoblastic leukemia (ALL) employ enzyme-based methods for depletion of blood asparagine in combination with standard chemotherapeutic agents.
  • Though the precise molecular mechanisms that result in the appearance of drug resistance are the subject of active study, potent ASNS inhibitors may have clinical utility in treating asparaginase-resistant forms of childhood ALL.
  • This review provides an overview of recent developments in our understanding of (a) the structure and catalytic mechanism of ASNS, and (b) the role that ASNS may play in the onset of drug-resistant childhood ALL.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7975-9 [10713115.001]
  • [Cites] Biochemistry. 2000 May 23;39(20):6003-11 [10821672.001]
  • [Cites] Plant Physiol. 2000 Jun;123(2):725-32 [10859202.001]
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26976-85 [10856289.001]
  • [Cites] Bioorg Med Chem Lett. 2000 Aug 21;10(16):1871-4 [10969988.001]
  • [Cites] Curr Opin Struct Biol. 2000 Aug;10(4):401-4 [10981625.001]
  • [Cites] Annu Rev Biochem. 2000;69:617-50 [10966471.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Aug;9(8):1767-75 [11060775.001]
  • [Cites] J Org Chem. 2000 Dec 1;65(24):8229-38 [11101378.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2329-37 [11206054.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23):6795-804 [11389593.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4347-68 [11390663.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Nat Struct Biol. 2001 Aug;8(8):684-9 [11473258.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Biochemistry. 2001 Sep 18;40(37):11168-75 [11551215.001]
  • [Cites] J Mol Biol. 2001 Nov 9;313(5):1093-102 [11700065.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47387-93 [11584022.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48100-7 [11677247.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Annu Rev Biochem. 2001;70:149-80 [11395405.001]
  • [Cites] Annu Rev Biochem. 2001;70:209-46 [11395407.001]
  • [Cites] Int J Biochem. 1980;11(6):519-39 [6103827.001]
  • [Cites] Annu Rev Biochem. 1980;49:877-919 [6250450.001]
  • [Cites] Cancer Res. 1981 Aug;41(8):3104-6 [6113889.001]
  • [Cites] Biochemistry. 1981 Dec 8;20(25):7226-32 [6119111.001]
  • [Cites] Anal Biochem. 1983 Apr 1;130(1):134-45 [6688159.001]
  • [Cites] Arch Biochem Biophys. 1985 Mar;237(2):335-46 [2858178.001]
  • [Cites] Arch Biochem Biophys. 1985 May 1;238(2):410-7 [2859838.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1914-9 [2868008.001]
  • [Cites] Biochemistry. 1985 Feb 26;24(5):1104-10 [2869778.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1321-3 [3464352.001]
  • [Cites] Am J Clin Oncol. 1986 Oct;9(5):411-5 [3465228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Mar;84(6):1565-9 [3470743.001]
  • [Cites] J Biol Chem. 1987 Aug 25;262(24):11565-70 [2887559.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Leukemia. 1989 Apr;3(4):294-7 [2564453.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2350-9 [2569668.001]
  • [Cites] Biochem Int. 1989 Mar;18(3):661-6 [2569873.001]
  • [Cites] Biochemistry. 1999 Dec 7;38(49):16146-57 [10587437.001]
  • [Cites] Protein Sci. 1999 Nov;8(11):2424-7 [10595545.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36498-504 [10593947.001]
  • [Cites] Bioorg Med Chem. 1999 Nov;7(11):2473-85 [10632057.001]
  • [Cites] Genetics. 2000 Feb;154(2):787-801 [10655230.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):C1691-9 [9176161.001]
  • [Cites] Trends Biochem Sci. 1997 Jun;22(6):211-6 [9204708.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):10168-77 [9254614.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):21661-4 [9268289.001]
  • [Cites] Nat Prod Rep. 1997 Aug;14(4):309-33 [9281835.001]
  • [Cites] Biochemistry. 1997 Sep 16;36(37):11061-8 [9333323.001]
  • [Cites] Nat Struct Biol. 1998 Jan;5(1):15-9 [9437423.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:87-144 [9559052.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98 [9559053.001]
  • [Cites] Cell Mol Life Sci. 1998 Mar;54(3):205-22 [9575335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9082-6 [9689037.001]
  • [Cites] Biochemistry. 1998 Sep 22;37(38):13230-8 [9748330.001]
  • [Cites] Annu Rev Biochem. 1998;67:693-720 [9759501.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):31691-701 [9822630.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):135-41 [10085237.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):151-8 [10085239.001]
  • [Cites] Chem Biol. 1999 Apr;6(4):R91-R105 [10099128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9479-84 [10449718.001]
  • [Cites] Acc Chem Res. 2003 Jul;36(7):539-48 [12859215.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302 [14499708.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38402-12 [12881527.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2003;32:335-73 [12574069.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40996-1002 [12890666.001]
  • [Cites] Biochemistry. 2004 Jan 13;43(1):9-18 [14705926.001]
  • [Cites] Leukemia. 2004 Mar;18(3):434-41 [14724653.001]
  • [Cites] Bioorg Chem. 2004 Apr;32(2):63-75 [14990305.001]
  • [Cites] Curr Top Med Chem. 2004;4(7):653-69 [15032680.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(6):669-81 [15052410.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Biochemistry. 2004 Jun 1;43(21):6447-63 [15157079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10000-5 [15220480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11269-74 [15277680.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Biochemistry. 2004 Aug 17;43(32):10328-42 [15301531.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):27-33 [15479734.001]
  • [Cites] J Biol Chem. 1968 Jan 25;243(2):376-80 [4295091.001]
  • [Cites] Science. 1968 May 3;160(3827):533-5 [5689413.001]
  • [Cites] Biochem Biophys Res Commun. 1968 Apr 5;31(1):43-7 [4869945.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2681-5 [5799144.001]
  • [Cites] J Biol Chem. 1969 Aug 10;244(15):4112-21 [4895361.001]
  • [Cites] J Biol Chem. 1989 Sep 15;264(26):15494-500 [2768274.001]
  • [Cites] Biochemistry. 1990 Jan 16;29(2):366-72 [1967948.001]
  • [Cites] Somat Cell Mol Genet. 1990 Jan;16(1):59-65 [1968681.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3509-13 [1972978.001]
  • [Cites] Protein Eng. 1990 Aug;3(8):739-44 [1977158.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6135-41 [1676298.001]
  • [Cites] Mol Cell Biol. 1991 Dec;11(12):6059-66 [1682798.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):144-9 [1346128.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 28;183(1):265-72 [1543496.001]
  • [Cites] Arch Biochem Biophys. 1992 May 15;295(1):120-5 [1349469.001]
  • [Cites] Biosci Biotechnol Biochem. 1992 Mar;56(3):376-9 [1369484.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):136-9 [1530118.001]
  • [Cites] Protein Eng. 1992 Apr;5(3):279-83 [1357656.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1993;66:203-309 [8430515.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3202-12 [8098842.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16771-80 [8102140.001]
  • [Cites] Biochemistry. 1994 Jan 25;33(3):675-81 [7904828.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7450-7 [7907328.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24304-9 [7929087.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26789-95 [7929415.001]
  • [Cites] Nature. 1995 Jan 19;373(6511):264-8 [7816145.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16585-91 [11867623.001]
  • [Cites] J Org Chem. 2002 May 17;67(10):3290-300 [12003538.001]
  • [Cites] J Org Chem. 2002 Jun 14;67(12):4372-5 [12054978.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24120-7 [11960987.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24579-83 [11967268.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jan;1(1):26-36 [12119606.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Cancer. 1970 Feb;25(2):306-20 [4905155.001]
  • [Cites] Annu Rev Pharmacol. 1970;10:421-40 [4911021.001]
  • [Cites] Ann Intern Med. 1971 Jun;74(6):893-901 [5281051.001]
  • [Cites] Cancer. 1971 Oct;28(4):819-24 [5286444.001]
  • [Cites] Transplantation. 1971 Nov;12(5):368-76 [4948688.001]
  • [Cites] Cancer. 1972 Aug;30(2):376-81 [4559405.001]
  • [Cites] J Biol Chem. 1973 Jun 10;248(11):3997-4002 [4145324.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1973;39:91-183 [4355768.001]
  • [Cites] Enzyme. 1975;19(5-6):314-28 [237754.001]
  • [Cites] J Med Chem. 1975 Sep;18(9):888-91 [240024.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1493-557 [14784.001]
  • [Cites] Cancer. 1979 Mar;43(3):1089-94 [284840.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Methods Enzymol. 1980;64:47-59 [7374457.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6566-74 [10490596.001]
  • [Cites] Nat Rev Drug Discov. 2004 Nov;3(11):935-49 [15520816.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50829-39 [15385533.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):855-61 [15602551.001]
  • [Cites] Med Res Rev. 2005 Mar;25(2):186-228 [15478125.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Mass Spectrom Rev. 2005 Mar-Apr;24(2):168-200 [15389855.001]
  • [Cites] Nat Rev Drug Discov. 2005 Apr;4(4):345-50 [15789121.001]
  • [Cites] Plant Physiol. 2005 Apr;137(4):1487 [15824288.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6681-8 [12215525.001]
  • [Cites] Nat Rev Drug Discov. 2002 Nov;1(11):882-94 [12415248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14752-7 [12409610.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7639-44 [12496246.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2743-7 [12433682.001]
  • [Cites] Arch Biochem Biophys. 2003 May 1;413(1):23-31 [12706338.001]
  • [Cites] Appl Microbiol Biotechnol. 2003 May;61(4):278-88 [12743756.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):603-9 [12628003.001]
  • [Cites] Org Lett. 2003 Jun 12;5(12):2033-6 [12790521.001]
  • [Cites] Biochemistry. 2003 Jun 17;42(23):7013-22 [12795596.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22964-71 [12684518.001]
  • [Cites] Biochem J. 1994 Dec 15;304 ( Pt 3):745-50 [7818476.001]
  • [Cites] Blood. 1995 Feb 1;85(3):751-6 [7833478.001]
  • [Cites] Proteins. 1994 Dec;20(4):347-55 [7731953.001]
  • [Cites] Methods Enzymol. 1995;249:284-312 [7791615.001]
  • [Cites] Nature. 1995 Nov 23;378(6555):416-9 [7477383.001]
  • [Cites] Nat Struct Biol. 1995 Dec;2(12):1102-8 [8846222.001]
  • [Cites] Nat Struct Biol. 1996 Jan;3(1):74-86 [8548458.001]
  • [Cites] J Bacteriol. 1996 Apr;178(8):2459-61 [8636057.001]
  • [Cites] J Med Chem. 1996 Jun 7;39(12):2367-78 [8691431.001]
  • [Cites] Med Res Rev. 1996 Jan;16(1):3-50 [8788213.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12384-92 [9139684.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Annu Rev Nutr. 2005;25:59-85 [16011459.001]
  • [Cites] Arch Biochem Biophys. 2005 Aug 1;440(1):18-27 [16023613.001]
  • [Cites] Nat Rev Drug Discov. 2005 Aug;4(8):649-63 [16056391.001]
  • (PMID = 16756505.001).
  • [ISSN] 0066-4154
  • [Journal-full-title] Annual review of biochemistry
  • [ISO-abbreviation] Annu. Rev. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA09126; United States / NIDDK NIH HHS / DK / DK52064; United States / NCI NIH HHS / CA / T32 CA009126; United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NCI NIH HHS / CA / CA107437; United States / NCI NIH HHS / CA / R21 CA107437
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 7006-34-0 / Asparagine; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  • [Number-of-references] 187
  • [Other-IDs] NLM/ NIHMS447419; NLM/ PMC3587692
  •  go-up   go-down


38. Li BS, Luo CY, He YY, Jiang H, Gu LJ: [Relationship between the antileukemic activity of L-asparaginase and Asn level around leukemic cells]. Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jul;12(7):557-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Following L-Asp treatment with designed concentrations and duration, the IC50 (inhibitory concentration 50%) of 8 kinds of common leukemia cell lines (U937, HL-60, Jurkat, NB4, THP-1, Namalwa, Karpass299, K562) were determined by CCK-8 assay.
  • There were significant differences in the sensitivities to L-Asp of different leukemia cell lines.
  • CONCLUSIONS: Different leukemia cell lines have different sensitivities to L-Asp, suggesting that exhaustion of asparagines around leukemia cells could not reflect the treatment efficacy of L-Asp.
  • L-Asp antileukemic activity is dose-dependent, which suggests the importance of high-dose L-Asp on childhood acute lymphoblastic leukemia.
  • [MeSH-major] Asparaginase / pharmacology. Asparagine / analysis. Leukemia / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Chromatography, High Pressure Liquid. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20637156.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


39. Pui CH: Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program; 2006;:142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment.
  • Improved treatment for acute lymphoblastic leukemia (ALL) has virtually eliminated testicular relapse.
  • However, the control of central nervous system (CNS) leukemia remains a therapeutic challenge in childhood ALL, partly because of the late complications arising from cranial irradiation.
  • In most current pediatric protocols, cranial irradiation (12 to 18 Gy) is given to 5% to 25% of patients--those with T-cell ALL, overt CNS disease (CNS3 status) or high-risk cytogenetics.
  • Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients.
  • Innovative treatment options are needed for children who develop CNS relapses after a short initial remission or after receiving cranial irradiation, and in any adults with CNS leukemia at diagnosis or relapse.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124053.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / CA-71907; United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


40. Simone JV: History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol; 2006;19(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] History of the treatment of childhood ALL: a paradigm for cancer cure.
  • The history of the treatment of childhood leukemia from 1950 to the present is reviewed here.
  • Strengths and weaknesses in the current treatment of childhood leukemia are discussed as well as possibilities for the future.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Therapy / history. Drug Therapy / methods. Drug Therapy / trends. Female. History, 20th Century. History, 21st Century. Humans. Male. Radiotherapy / history. Radiotherapy / methods. Radiotherapy / trends. Survival Rate / trends

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516133.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


41. Schmitz NM, Hirt A, Aebi M, Leibundgut K: Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol; 2006 Sep;169(3):1074-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
  • In Nalm-6 acute lymphoblastic leukemia extracts, serine 608 is phosphorylated by CDK4/6 complexes but not by CDK2.
  • Serine 612 phosphorylation by CDK4 also occurred in extracts of childhood acute lymphoblastic leukemia cells but not in extracts of mobilized CD34+ hemopoietic progenitor cells.
  • This phenomenon could contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and explain their refractoriness to differentiation-inducing agents.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Processing, Post-Translational. Retinoblastoma-Like Protein p107 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):562-70 [10698526.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4320-3 [10969768.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):877-84 [10973815.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19358-66 [12646568.001]
  • [Cites] Cell. 2003 Aug 22;114(4):431-43 [12941272.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4794-803 [12970191.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):779-86 [15081408.001]
  • [Cites] Cell. 2004 Apr 16;117(2):239-51 [15084261.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Cell. 1991 May 3;65(3):381-93 [2018973.001]
  • [Cites] Cell. 1991 Oct 18;67(2):293-302 [1655277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6914-8 [8346196.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Leukemia. 1994 Jun;8(6):940-5 [8207988.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3215-20 [8622916.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1093-106 [16360038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]
  • [Cites] Leukemia. 2001 Jan;15(1):1-9 [11243375.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4773-84 [11416152.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] EMBO Rep. 2001 Sep;2(9):794-9 [11520855.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):60-5 [12542976.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8313-20 [8626527.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7173-81 [8943373.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):249-54 [9010227.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):366-8 [9029026.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12738-46 [9139732.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5771-83 [9315635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704 [9380698.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):765-9 [9635861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9463-71 [10092628.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):692-6 [10231867.001]
  • [Cites] Cell. 1999 Sep 17;98(6):859-69 [10499802.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):591-8 [15950907.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):1002-11 [15941859.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):831-6 [16007079.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1783-7 [16107892.001]
  • (PMID = 16936279.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Indoles; 0 / Multiprotein Complexes; 0 / Retinoblastoma-Like Protein p107; 114719-57-2 / fascaplysine; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC1698824
  •  go-up   go-down


42. Baillargeon J, Langevin AM, Lewis M, Estrada J, Mullins J, Pitney A, Ma JZ, Chisholm GB, Pollock BH: Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2006 Sep;28(9):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL), the most common malignancy in children, constitutes 25% of all pediatric cancer.
  • Childhood cancer patients who are obese at diagnosis represent a particular challenge for the oncologist.
  • Obesity may complicate chemotherapy dose determination, and has been associated with decreased overall and event-free survival in a number of adult cancer patients, and more recently in pediatric patients.
  • The purpose of the present study was to examine whether obesity at diagnosis was associated with decreased overall and event-free survival in a cohort of 322 predominantly Hispanic pediatric patients with B-precursor ALL.
  • [MeSH-major] Obesity / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Body Mass Index. Child. Child, Preschool. Disease-Free Survival. Female. Hispanic Americans. Humans. Male. Survival Analysis


43. Poppe B, Cauwelier B, Van Limbergen H, Yigit N, Philippé J, Verhasselt B, De Paepe A, Benoit Y, Speleman F: Novel cryptic chromosomal rearrangements in childhood acute lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization. Haematologica; 2005 Sep;90(9):1179-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel cryptic chromosomal rearrangements in childhood acute lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization.
  • BACKGROUND AND OBJECTIVES: It is often difficult to obtain good karyotypes of cells from children with acute lymphoblastic leukemia (ALL) because of poor morphology and spreading.
  • Our objective was to search for cryptic rearrangements in childhood ALL.
  • DESIGN AND METHODS: A series of eight cases of childhood ALL with at least two structural defects were selected and studied by multiple color fluorescent in situ hybridization (M-FISH).
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Karyotyping / methods. Male


44. Kesler SR, Tanaka H, Koovakkattu D: Cognitive reserve and brain volumes in pediatric acute lymphoblastic leukemia. Brain Imaging Behav; 2010 Dec;4(3-4):256-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive reserve and brain volumes in pediatric acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is associated with long-term, progressive cognitive deficits and white matter injury.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):837-43 [19117694.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):156-61 [19405135.001]
  • [Cites] Hum Genet. 2009 Jul;126(1):215-32 [19294424.001]
  • [Cites] Neurology. 2009 Aug 4;73(5):356-61 [19652139.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1172:63-9 [19743551.001]
  • [Cites] Brain Res Rev. 2009 Oct;61(2):221-39 [19631687.001]
  • [Cites] Acta Neurochir Suppl. 2010;106:195-7 [19812948.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1065-82, vi-vii [19825453.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Nov;30(10):1947-54 [19643920.001]
  • [Cites] Prog Neurobiol. 2009 Dec;89(4):369-82 [19819293.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):70-85 [19657332.001]
  • [Cites] J Int Neuropsychol Soc. 2010 Jan;16(1):94-105 [19835663.001]
  • [Cites] Lang Speech Hear Serv Sch. 2010 Jan;41(1):70-83 [19948772.001]
  • [Cites] J Head Trauma Rehabil. 2010 Jan-Feb;25(1):15-22 [20051899.001]
  • [Cites] J Clin Exp Neuropsychol. 2009 Oct;31(7):868-76 [19333862.001]
  • [Cites] J Pediatr Psychol. 2010 Jul;35(6):662-71 [19820170.001]
  • [Cites] Pediatrics. 2005 Aug;116(2):333-41 [16061586.001]
  • [Cites] J Pediatr. 2006 Jan;148(1):72-7 [16423601.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3 Suppl 2):S69-74 [16917199.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):456-61 [11070477.001]
  • [Cites] J Int Neuropsychol Soc. 2001 Jul;7(5):640-6 [11459115.001]
  • [Cites] Neuroimage. 2001 Jul;14(1 Pt 1):21-36 [11525331.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):88-92 [12461791.001]
  • [Cites] Dev Neuropsychol. 2002;22(2):455-69 [12537333.001]
  • [Cites] J Clin Exp Neuropsychol. 2003 Aug;25(5):594-613 [12815498.001]
  • [Cites] J Clin Exp Neuropsychol. 2003 Aug;25(5):625-33 [12815500.001]
  • [Cites] Neuroimage. 2003 Jul;19(3):1215-27 [12880846.001]
  • [Cites] Appl Neuropsychol. 2003;10(3):153-62 [12890641.001]
  • [Cites] Psychol Sci. 2003 Nov;14(6):623-8 [14629696.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Nat Rev Neurosci. 2004 Jun;5(6):471-82 [15152197.001]
  • [Cites] Int J Methods Psychiatr Res. 2004;13(3):141-51 [15297898.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Demography. 1998 Feb;35(1):71-81 [9512911.001]
  • [Cites] Am J Phys Med Rehabil. 2005 Jan;84(1):62-75 [15632490.001]
  • [Cites] Cereb Cortex. 2005 Apr;15(4):394-402 [15749983.001]
  • [Cites] J Child Neurol. 2005 Feb;20(2):129-33 [15794179.001]
  • [Cites] Pharmacotherapy. 2005 May;25(5):748-55 [15899736.001]
  • [Cites] J Fam Psychol. 2005 Jun;19(2):294-304 [15982107.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] Prog Brain Res. 2006;157:199-206 [17046672.001]
  • [Cites] Arch Clin Neuropsychol. 2006 Oct;21(7):711-20 [17071362.001]
  • [Cites] Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007 Jan;14(1):40-54 [17164189.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1082-7 [17219132.001]
  • [Cites] Gerontologist. 2007 Jun;47(3):307-22 [17565095.001]
  • [Cites] Clin Neuropsychol. 2007 Jul;21(4):638-52 [17613982.001]
  • [Cites] Dev Psychol. 2007 Nov;43(6):1497-512 [18020827.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):513-20, 520.e1 [18346506.001]
  • [Cites] Curr Opin Psychiatry. 2008 May;21(3):296-302 [18382231.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • [Cites] J Magn Reson Imaging. 2008 Jun;27(6):1250-5 [18504742.001]
  • [Cites] Neuroimage. 2008 Jul 1;41(3):903-13 [18424084.001]
  • [Cites] Behav Brain Res. 2008 Sep 1;192(1):137-42 [18378330.001]
  • [Cites] J Consult Clin Psychol. 2008 Jun;76(3):367-78 [18540731.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] J Int Neuropsychol Soc. 2008 Sep;14(5):869-77 [18764982.001]
  • [Cites] Dev Neurorehabil. 2008 Jul;11(3):174-86 [18781502.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2691-700 [18491104.001]
  • [Cites] Dev Disabil Res Rev. 2008;14(3):185-95 [18924154.001]
  • [Cites] Prog Neurobiol. 2008 Nov;86(3):141-55 [18824075.001]
  • [Cites] Acta Paediatr. 2009 Jan;98(1):180-6 [18826490.001]
  • [Cites] Biol Psychol. 2009 Feb;80(2):256-9 [19022337.001]
  • [Cites] Pediatr Blood Cancer. 2009 Apr;52(4):447-54 [19061221.001]
  • [Cites] Am J Geriatr Psychiatry. 2009 Mar;17(3):175-8 [19225275.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2212-24 [19228974.001]
  • [Cites] J Pediatr Psychol. 2009 Apr;34(3):317-27 [18667478.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):465-70 [19395901.001]
  • [Cites] Neurobiol Aging. 2009 Jul;30(7):1114-24 [18053618.001]
  • [Cites] Neuropsychologia. 2009 Aug;47(10):2015-28 [19467352.001]
  • [Cites] Behav Genet. 2009 Jul;39(4):393-405 [19377873.001]
  • (PMID = 20814845.001).
  • [ISSN] 1931-7565
  • [Journal-full-title] Brain imaging and behavior
  • [ISO-abbreviation] Brain Imaging Behav
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134639-01A1; United States / NCI NIH HHS / CA / K07 CA134639; United States / NICHD NIH HHS / HD / R24 HD050836; United States / NCI NIH HHS / CA / K07 CA134639-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS275369; NLM/ PMC3049995
  •  go-up   go-down


45. Hoffmann K, Firth MJ, Beesley AH, Freitas JR, Ford J, Senanayake S, de Klerk NH, Baker DL, Kees UR: Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index. Br J Haematol; 2008 Mar;140(6):656-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.
  • Despite high cure rates 25% of children with acute lymphoblastic leukaemia (ALL) relapse and have dismal outcome.
  • The data demonstrate the feasibility of using GEP to improve risk stratification in childhood ALL.
  • [MeSH-major] Gene Expression Profiling / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Bone Marrow Examination / methods. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Models, Genetic. Oligonucleotide Array Sequence Analysis / methods. Prognosis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Assessment / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302714.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


46. Ivanovski PI, Ivanovski IP: Childhood acute lymphoblastic leukemia is triggered by the introduction of immunization against diphtheria. Med Hypotheses; 2007;68(2):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukemia is triggered by the introduction of immunization against diphtheria.
  • BACKGROUND: Childhood acute lymphoblastic leukemia has prenatal origin.
  • Leukemogenic translocations originating during fetal life are insufficient for overt leukemia.
  • Transgenic TEL-AML1 mice have failed to develop leukemia.
  • Since then, childhood leukemia has almost unchangeable incidence.
  • HYPOTHESIS: Childhood acute lymphoblastic leukemia is triggered by vaccination against diphtheria.
  • TESTING THE HYPOTHESIS: Epidemiological survey for leukemia cases among "exemptors" and unvaccinated cases among ALL children should be done.
  • IMPLICATIONS OF THE HYPOTHESIS: If there is no leukemia among the "exemptors", no unvaccinated among ALL, and some mice develop leukemia upon vaccination childhood leukemia will be prevented by massive neonatal screening for leukemogenic genetics and/or with a new vaccination schedule.
  • [MeSH-major] Diphtheria Toxoid / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Animals. Child. Disease Models, Animal. Humans. Incidence. Mice


47. Wu MY, Li CK, Li ZG: [Considerations on the treatment strategies of childhood acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2010 Mar;48(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Considerations on the treatment strategies of childhood acute lymphoblastic leukemia].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Child. Humans


48. Lyons R, Williams O, Morrow M, Sebire N, Hubank M, Anderson J: The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. Leuk Res; 2010 Jan;34(1):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TEL-AML1 is an oncogenic fusion protein associated with childhood pre-B acute lymphoblastic leukaemia.
  • From published microarray datasets we identified the Rho Guanine Nucleotide Exchange Factor (RhoGEF) Asef to be associated with TEL-AML1 leukaemia.
  • [MeSH-major] Cell Transformation, Neoplastic. Core Binding Factor Alpha 2 Subunit / physiology. Guanine Nucleotide Exchange Factors / physiology. Leukemia / pathology. Oncogene Proteins, Fusion / physiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19628279.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARHGEF4 protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Guanine Nucleotide Exchange Factors; 0 / Oncogene Proteins, Fusion; 0 / Rho Guanine Nucleotide Exchange Factors; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


49. Rihani R, Bazzeh F, Faqih N, Sultan I: Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer; 2010 Sep 15;116(18):4385-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
  • The main histological subtype of secondary hematological malignancy was acute myeloid leukemia (AML) (49%), which had the shortest median latency time and the worst 5-year survival (18% ± 5.3%; P = .044).
  • The risk of secondary AML steadily increased from 1986 to 2005, whereas SIRs for acute lymphoblastic leukemia did not change over time.
  • CONCLUSIONS: Childhood cancer survivors are at increased risk of developing secondary hematological malignancies, particularly secondary AML.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. SEER Program. Time Factors

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20549819.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Rimmer RB, Weigand S, Foster KN, Wadsworth MM, Jacober K, Matthews MR, Drachman D, Caruso DM: Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community. J Burn Care Res; 2008 Jul-Aug;29(4):595-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community.
  • Arizona Burn Center staff observed an increasing number of pediatric scald burn admissions.
  • Arizona Burn Center scald admission variables (ages 0-5 years) reviewed included age, sex, ethnicity, TBSA, body parts burned, occurrence month and location, caregiver present, child and caregiver activities when injured, payor source, length of stay, parental language, and zip code.
  • There were a total of 170 pediatric patients, aged 0 to 5 years, admitted to the burn center during 2005 to 2006.
  • Of this total, 124 of the patients were admitted for scald burns, accounting for 59% of all pediatric burn admissions.
  • The remaining pediatric admissions for children aged 0 to 5 were for burns caused by fire or flame 15%, contact with a hot object 13%, friction burns 7%, chemical burns 3%, and electrical burns 3%.
  • Most common child behaviors were pulling hot substance from stove (24%), from countertop (13%), and having liquid spilled on them (13%) typically while caregiver was cooking.
  • Scalds occurred in the kitchen (83%) and mainly in child's home (94%).
  • Results suggest that culturally sensitive, bilingual scald prevention education, targeting Hispanics, is needed to create awareness of the frequency, severity, and danger associated with pediatric scalds.
  • [MeSH-minor] Accidents, Home / statistics & numerical data. Arizona / epidemiology. Burn Units. Child, Preschool. Cooking. Female. Focus Groups. Health Education. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay / statistics & numerical data. Male. Patient Admission / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535476.001).
  • [ISSN] 1559-047X
  • [Journal-full-title] Journal of burn care & research : official publication of the American Burn Association
  • [ISO-abbreviation] J Burn Care Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Harned TM, Gaynon PS: Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag; 2008 Apr;4(2):327-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating refractory leukemias in childhood, role of clofarabine.
  • Approximately 4000 children and adolescents under the age of 20 years develop acute leukemia per year in the US.
  • Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer.
  • Despite impressive improvements in outcome, relapsed ALL is the fourth most common pediatric malignancy.
  • Therapy for relapsed ALL remains unsatisfactory, and the majority of relapse patients still succumb to leukemia.
  • Between one-third and one-half of patients with acute myelogenous leukemia (AML) relapse, and no standard therapy is recognized for patients with relapsed and/or refractory AML.
  • Phase I and II single-agent trials in children have shown that clofarabine is safe and active in both myeloid and lymphoid relapsed/refractory acute leukemias.
  • Clofarabine has been approved by the FDA for pediatric patients with relapsed/refractory ALL after at least 2 prior therapeutic attempts.

  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):9-16 [17252564.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):515-20 [10051535.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):851-9 [10519984.001]
  • [Cites] J Biol Chem. 1951 Oct;192(2):505-18 [14907641.001]
  • [Cites] Cancer Res. 1954 May;14(4):294-8 [13160953.001]
  • [Cites] Ann N Y Acad Sci. 1950 Jul 7;52(8):1318-35 [15433149.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9 [15309512.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3537-43 [11071652.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3142-53 [11408512.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2001;19:21-45 [11686015.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3580-9 [11705880.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Blood. 2003 May 15;101(10):3868-71 [12543868.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2940-7 [12885813.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] J Clin Pharmacol. 2004 Nov;44(11):1309-22 [15496649.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1191-8 [3114435.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4 [1348362.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cancer. 2005 May 15;103(10):1985-95 [15803490.001]
  • [Cites] Drug Metab Dispos. 2005 Jun;33(6):739-48 [15743978.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):369-70 [15902772.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S12-3 [15962525.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(2):311-20 [16516128.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4011-7 [16818700.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):855-63 [17016426.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2764-9 [16809615.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Feb;7(2):113-8 [17288522.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • (PMID = 18728851.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2504075
  • [Keywords] NOTNLM ; childhood / clofarabine / leukemia / pediatric / refractory
  •  go-up   go-down


52. Motwani J, Jesson J, Sturch E, Jones S, Eyre L, Short P, Davies P, Williams MD, Darbyshire PJ, Hill FG, Lawson S: Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre. Br J Haematol; 2009 Jan;144(1):133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Remission Induction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016737.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Ashton LJ, Gifford AJ, Kwan E, Lingwood A, Lau DT, Marshall GM, Haber M, Norris MD: Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia. Leukemia; 2009 Jul;23(7):1348-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Membrane Transport Proteins / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Homozygote. Humans. Polymerase Chain Reaction. Reduced Folate Carrier Protein. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340000.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


54. Jeon IS, Yi DY: Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus. Pediatr Hematol Oncol; 2009 Mar;26(2):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
  • Acute lymphoblastic leukemia (ALL), a primary hematologic malignancy that is especially common in childhood, occurs relatively rarely as a secondary malignant neoplasm.
  • ALL, FAB L2, and immunophenotypically pro-B developed 16 months after the final chemotherapy treatment.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Perivascular Epithelioid Cell Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Uterine Neoplasms / complications
  • [MeSH-minor] Anthracyclines / adverse effects. Child. Cytogenetic Analysis. Female. Humans. Precursor Cells, B-Lymphoid / pathology. Topoisomerase II Inhibitors. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322738.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


55. Malempati S, Tibbitts D, Cunningham M, Akkari Y, Olson S, Fan G, Sears RC: Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia; 2006 Sep;20(9):1572-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias.
  • We examined whether aberrant protein stabilization could be a mechanism of c-Myc overexpression in leukemia cell lines and in primary bone marrow samples from pediatric acute lymphoblastic leukemia (ALL) patients.
  • We found that c-Myc protein half-life was prolonged in the majority of leukemia cell lines and bone marrow samples tested.
  • There were no mutations in the c-myc gene in any of the leukemia cell lines that could account for increased c-Myc stability.
  • However, abnormal phosphorylation at two conserved sites, Threonine 58 and Serine 62, was observed in leukemia cell lines with stabilized c-Myc.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32475-81 [10913153.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2275-84 [12399973.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25802-7 [12734207.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51606-12 [14563837.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] EMBO J. 2004 May 19;23(10):2116-25 [15103331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90 [15150404.001]
  • [Cites] Nature. 1982 Sep 2;299(5878):61-3 [6955596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1983 Aug 18-24;304(5927):596-602 [6308472.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):603-10 [6606489.001]
  • [Cites] Blood. 1984 Dec;64(6):1234-9 [6208953.001]
  • [Cites] Mol Cell Biol. 1984 Nov;4(11):2486-97 [6513926.001]
  • [Cites] Nature. 1986 Aug 28-Sep 3;322(6082):848-50 [3528863.001]
  • [Cites] Annu Rev Genet. 1986;20:361-84 [3028245.001]
  • [Cites] Mol Cell Biol. 1987 Dec;7(12):4513-21 [3325826.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;141:82-93 [3215058.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):3952-64 [2196440.001]
  • [Cites] Genes Dev. 1990 Dec;4(12A):2025-35 [2269425.001]
  • [Cites] Oncogene. 1991 May;6(5):797-805 [2052358.001]
  • [Cites] Genes Dev. 1993 Apr;7(4):671-82 [8458579.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3383-6 [8012955.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5510-22 [8035827.001]
  • [Cites] Blood. 1994 Aug 1;84(3):883-8 [8043869.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2439-44 [8570196.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5513-8 [8621409.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5961-9 [9742113.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):185-93 [9931326.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):169-79 [10078200.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1133-7 [15467447.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2423-35 [10713166.001]
  • (PMID = 16855632.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100855-02; United States / NCI NIH HHS / CA / CA086957-05; United States / NCI NIH HHS / CA / R01 CA100855; United States / NCI NIH HHS / CA / CA100855-02; United States / NCI NIH HHS / CA / K01 CA086957; United States / NCI NIH HHS / CA / K01 CA086957-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.4.99.- / ATP dependent 26S protease
  • [Other-IDs] NLM/ NIHMS42996; NLM/ PMC2322939
  •  go-up   go-down


56. Hammer LD, Curry ES, Harlor AD, Laughlin JJ, Leeds AJ, Lessin HR, Rodgers CT, Granado-Villar DC, Brown JM, Cotton WH, Gaines BM, Gambon TB, Gitterman BA, Gorski PA, Kraft CA, Marino RV, Paz-Soldan GJ, Zind B, Committee on Practice and Ambulatory Medicine, Council on Community Pediatrics: Increasing immunization coverage. Pediatrics; 2010 Jun;125(6):1295-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from the 2007 National Immunization Survey showed that 90% of children 19 to 35 months of age have received recommended doses of each of the following vaccines: inactivated poliovirus (IPV), measles-mumps-rubella (MMR), varicella-zoster virus (VZB), hepatitis B virus (HBV), and Haemophilus influenzae type b (Hib).
  • These challenges include an increase in new vaccines and new vaccine combinations as well as a significant number of vaccines currently under development; a dramatic increase in the acquisition cost of vaccines, coupled with a lack of adequate payment to practitioners to buy and administer vaccines; unanticipated manufacturing and delivery problems that have caused significant shortages of various vaccine products; and the rise of a public antivaccination movement that uses the Internet as well as standard media outlets to advance a position, wholly unsupported by any scientific evidence, linking vaccines with various childhood conditions, particularly autism.
  • Pediatricians should work individually and collectively at the local, state, and national levels to ensure that all children without a valid contraindication receive all childhood immunizations on time.
  • Pediatricians and pediatric organizations, in conjunction with government agencies such as the Centers for Disease Control and Prevention, must communicate effectively with parents to maximize their understanding of the overall safety and efficacy of vaccines.
  • [MeSH-minor] Child. Financing, Government / economics. Financing, Government / statistics & numerical data. Health Services Accessibility / economics. Healthy People Programs / standards. Humans. Immunization Schedule. Insurance Coverage. Practice Management, Medical / organization & administration. Public Sector / economics. Vaccines / economics


57. Scrideli CA, Cortez MA, Yunes JA, Queiróz RG, Valera ET, da Mata JF, Toledo SR, Pavoni-Ferreira P, Lee ML, Petrilli AS, Brandalise SR, Tone LG: mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res; 2010 Jan;34(1):32-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor.
  • Our data address new information in the complex interaction of the migration/adhesion genes and childhood ALL.
  • [MeSH-major] Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / genetics. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-2 / genetics
  • [MeSH-minor] Base Sequence. Child. Child, Preschool. DNA Primers. Flow Cytometry. Humans. Infant. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19875168.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


58. Dokmanovic L, Urosevic J, Janic D, Jovanovic N, Petrucev B, Tosic N, Pavlovic S: Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Ther Drug Monit; 2006 Dec;28(6):800-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
  • The aim of this study was to determine the frequency and type of TPMT polymorphisms in the population of Serbia and Montenegro and to assess its relevance in the management of childhood acute lymphoblastic leukemia (ALL).
  • In the study of 50 patients with childhood ALL treated according to the BFM-like protocol, it was found that even TPMT-heterozygous patients are at greater risk of thiopurine drug-related leukopenia (mean duration of period when children missed therapy as a result of leukopenia for TPMT-heterozygous patients was 11.3 weeks vs 3.4 weeks for wild-type genotype patients, P < 0.01).
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Methyltransferases / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Drug Tolerance. Humans. Male. Retrospective Studies. Yugoslavia

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164697.001).
  • [ISSN] 0163-4356
  • [Journal-full-title] Therapeutic drug monitoring
  • [ISO-abbreviation] Ther Drug Monit
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


59. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P: Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res; 2006 Oct;29(10):866-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The leukemic cells were collected from 78 childhood leukemia patients admitted at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, in the period from July 2003 to February 2005.
  • There were 61 cases of acute lymphoblastic leukemia (ALL), 14 cases of acute myeloblastic leukemia (AML), and 3 cases of chronic myelocytic leukemia (CML).
  • Thus, curcumin treatment may provide a lead for clinical treatment of leukemia patients in the future.
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow / drug effects. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Survival / drug effects. Child, Preschool. Female. Humans. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myeloid / blood. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / genetics. RNA, Messenger / isolation & purification. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121181.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; IT942ZTH98 / Curcumin
  •  go-up   go-down


60. Barber LM, Barlow RA, Meyer S, White DJ, Will AM, Eden TO, Taylor GM: Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia. Br J Haematol; 2005 Sep;130(5):796-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia.
  • [MeSH-major] Alternative Splicing. Fanconi Anemia / genetics. Genes, BRCA2. Leukemia, Myeloid / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Disease Susceptibility. Exons. Fanconi Anemia Complementation Group D2 Protein. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 May;133(4):446-8; author reply 448 [16643458.001]
  • [ErratumIn] Br J Haematol. 2005 Dec;131(5):672
  • (PMID = 16115142.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; 0 / Nuclear Proteins
  •  go-up   go-down


61. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • Here, I describe that succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia.
  • Examination of the PBMC cell-type subsets identifies monocytes and natural killer (NK) cells as primary sources of the mutant transcript, although lesser contributions also come from B and T lymphocytes.
  • Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational mechanism targeting SDHB is operational in T-cell acute leukemia.
  • Accordingly, substantial levels (more than 3%) of the mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow samples, but in none of 20 B-ALL samples.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


62. Unal S, Tuncer AM, Cetin M, Yetgin S: The absence of peripheral blood blasts at diagnosis may predict CNS involvement or CNS relapse in pediatric acute lymphoblastic leukemia patients. Turk J Pediatr; 2008 Nov-Dec;50(6):537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absence of peripheral blood blasts at diagnosis may predict CNS involvement or CNS relapse in pediatric acute lymphoblastic leukemia patients.
  • A high tumor burden at the time of diagnosis of childhood acute lymphoblastic leukemia has an unfavorable outcome.
  • [MeSH-major] Blast Crisis / pathology. Central Nervous System Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Analysis of Variance. Chi-Square Distribution. Child. Child, Preschool. Female. Humans. Male. Predictive Value of Tests. Recurrence. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227416.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


63. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S: The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res; 2006 Sep 15;12(18):5526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
  • PURPOSE: Thalidomide and its analogues have shown promise in the treatment of multiple myeloma but their therapeutic potential has not been evaluated in models of acute lymphoblastic leukemia (ALL).
  • EXPERIMENTAL DESIGN: We assessed the effects of the thalidomide analogue, CC-4047, on the growth and apoptosis signaling of human B cell precursor (BCP) ALL cell lines and freshly obtained childhood BCP-ALL cells grown with or without stromal cells.
  • In contrast with the antileukemic effect of cytarabin, this was more pronounced when cell lines or freshly obtained childhood BCP-ALL cells were cocultured with stromal cells.
  • The inhibition of tumor growth, caspase-3 cleavage, and reduced microvessel density was observed in nonobese diabetic/severe combined immunodeficiency mice inoculated s.c. with childhood BCP-ALL cells upon CC-4047 treatment.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Animals. Blood Vessels / drug effects. Caspase 3 / metabolism. Child, Preschool. Female. Humans. Infant. Male. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation / pathology. Neovascularization, Pathologic / drug therapy. Stromal Cells / drug effects. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000689.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; D2UX06XLB5 / pomalidomide; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


64. Davidsson J, Lilljebjörn H, Andersson A, Veerla S, Heldrup J, Behrendtz M, Fioretos T, Johansson B: The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet; 2009 Nov 1;18(21):4054-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The DNA methylome of pediatric acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with high hyperdiploidy [51-67 chromosomes] and the t(12;21)(p13;q22) [ETV6/RUNX1 fusion] representing the most frequent abnormalities.
  • [MeSH-major] CpG Islands / genetics. DNA Methylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Apoptosis Regulatory Proteins / genetics. Caveolin 1 / genetics. Child. Chromosome Mapping. Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Profiling. Genome, Human / genetics. Genome-Wide Association Study. Humans. Intracellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins / genetics. Sequence Analysis, DNA / methods. Thiolester Hydrolases. Tumor Suppressor Proteins / genetics. bcl-Associated Death Protein / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679565.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / BAD protein, human; 0 / BBC3 protein, human; 0 / CAV1 protein, human; 0 / CDK2AP1 protein, human; 0 / Caveolin 1; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / PRKCDBP protein, human; 0 / Proto-Oncogene Proteins; 0 / TEL-AML1 fusion protein; 0 / Tumor Suppressor Proteins; 0 / bcl-Associated Death Protein; 117896-08-9 / nucleophosmin; EC 3.1.2.- / THEM4 protein, human; EC 3.1.2.- / Thiolester Hydrolases
  •  go-up   go-down


65. Thelander EF, Ichimura K, Corcoran M, Barbany G, Nordgren A, Heyman M, Berglund M, Mungall A, Rosenquist R, Collins VP, Grandér D, Larsson C, Lagercrantz S: Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Mar;49(3):477-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia.
  • Using a chromosome 6 specific tile path array, 60 samples from in total 49 cases with mantle cell lymphoma (MCL), de novo diffuse large B-cell lymphoma (DLBCL), transformed DLBCL as well as preceding follicular lymphoma (FL), and childhood acute lymphoblastic leukemia (ALL), were characterized.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 6. Lymphoma, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297524.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Repressor Proteins; 0 / Transcription Factors; 138415-26-6 / PRDM1 protein, human; EC 6.3.2.19 / HACE1 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


66. Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol; 2009 Nov;24(11):1409-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas.
  • Pediatric high-grade gliomas represent approximately 10% of all pediatric brain tumors.
  • In this review, we present an overview of both pediatric high-grade gliomas and diffuse intrinsic pontine gliomas with a focus on their epidemiology, etiology, presentation, prognostic factors, biology, treatment modalities, outcomes, and future research directions.
  • [MeSH-minor] Child. Humans. Models, Neurological. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638636.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


67. Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I: High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Sep;49(3):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Most survivors of childhood acute lymphoblastic leukemia (ALL) and T-cell lymphoma (T-NHL) treated before 1990 received cranial radiation.
  • CONCLUSIONS: Survivors of childhood ALL treated with cranial radiation require prolonged surveillance because of a high incidence of late meningiomas.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. Israel / epidemiology. Male


68. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • The molecular basis of susceptibility to childhood malignant hemopathy remains largely unknown.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • Functional analysis of the murine Hoxd4 homolog revealed that mutant Hoxd4 protein had lower transcriptional activity than wild-type protein in vitro.
  • The p.Glu81Val mutation of HOXD4 thus results in a partial loss-of-function, which might be involved in childhood ALL.
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Animals. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. Female. Haplotypes. Humans. Infant. Male. Mice. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


69. Costa ES, Thiago LS, Otazu IB, Ornellas MH, Land MG, Orfao A: An uncommon case of childhood biphenotypic precursor-B/T acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Apr;50(4):941-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon case of childhood biphenotypic precursor-B/T acute lymphoblastic leukemia.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Stem Cells / pathology. T-Lymphocytes / pathology


70. Norén-Nyström U, Roos G, Bergh A, Botling J, Lönnerholm G, Porwit A, Heyman M, Forestier E: Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia; 2008 Mar;22(3):504-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome.
  • We retrospectively evaluated reticulin fiber density (RFD) in 166 diagnostic bone marrow (BM) biopsies and 62 biopsies obtained at treatment day 29 from children with acute lymphoblastic leukemia (ALL).
  • Patients with B-cell precursor (BCP)-ALL showed higher RFD as compared to patients with T-cell ALL (P<0.001).
  • To our knowledge, these findings are novel and may indicate BM fibrosis as a new valuable prognostic marker in childhood ALL.
  • [MeSH-major] Bone Marrow Examination. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Primary Myelofibrosis / pathology. Reticulin / analysis
  • [MeSH-minor] Adolescent. Aneuploidy. Biopsy. Child. Child, Preschool. Female. Humans. Infant. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / therapy. Male. Neoplasm, Residual. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Sweden / epidemiology. Treatment Outcome


71. Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH: Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer; 2005 Jan 15;103(2):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
  • BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy.
  • CONCLUSIONS: Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / epidemiology. Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Probability. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15599932.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Rowe JM: Optimal management of adults with ALL. Br J Haematol; 2009 Feb;144(4):468-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.
  • The remarkable progress in childhood ALL has not been replicated in adult ALL and approximately two thirds of patients younger than 60 years, and more than 90% of those over 60 years, are expected to succumb to their disease.
  • Prognostic factors have been more clearly defined, moving cytogenetics and molecular determinants forefront, much like acute myeloid leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055668.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


73. Morrissette JJ, Halligan GE, Punnett HH, McKenzie AS, Guerrero F, de Chadarévian JP: Down syndrome with low hypodiploidy in precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2006 Aug;169(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down syndrome with low hypodiploidy in precursor B-cell acute lymphoblastic leukemia.
  • We describe the rare finding of a 33-month-old child neonatally diagnosed with Down syndrome, who presented with pre-B acute lymphoblastic leukemia (ALL) with a pretreatment bone marrow karyotype in which a low hypodiploid cell line (38 chromosomes) was identified in 17/19 cells studied.
  • Hypodiploidy (loss of one or more chromosomes) is seen in approximately 5% of all childhood pre-B ALL cases and in approximately 2.2% cases of individuals with a constitutional trisomy 21.
  • Low hypodiploidy, associated with a high risk of relapse, is rare in pediatric ALL cases in the general population, and, to our knowledge, is previously unreported in patients with trisomy 21.
  • [MeSH-minor] Child, Preschool. Female. Humans. Karyotyping. Male


74. Olsen M, Madsen HO, Hjalgrim H, Gregers J, Rostgaard K, Schmiegelow K: Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood. J Pediatr Hematol Oncol; 2006 Nov;28(11):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cell precursor acute lymphoblastic leukemia (ALL), where it occurs in 25% of all cases.
  • The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-positive cells in peripheral blood in both childhood and adulthood.
  • [MeSH-minor] Adult. Blood Donors. Child. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114960.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


75. Frangoul H, Al-Jadiry MF, Shyr Y, Ye F, Shakhtour B, Al-Hadad SA: Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990-2002. N Engl J Med; 2008 Jul 24;359(4):435-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990-2002.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / supply & distribution. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Child. Child, Preschool. Humans. Infant. Iraq / epidemiology. Multivariate Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650525.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT: Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer; 2005 Jul;45(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis.
  • BACKGROUND: The optimal management of childhood acute lymphoblastic leukemia (ALL) with hyperleukocytosis is unclear, largely because the risk of leukostasis-related complications is poorly characterized.
  • PROCEDURE: We reviewed the presenting characteristics, initial management, and frequency and type of complications in all children seen at St. Jude Children's Research Hospital with previously untreated ALL and an initial leukocyte count >200 x 10(9)/L.
  • CONCLUSIONS: Serious leukostasis-related complications are relatively uncommon in childhood ALL and most occur at presentation.
  • [MeSH-major] Leukocytosis / complications. Leukostasis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / epidemiology. Acute Kidney Injury / etiology. Acute Kidney Injury / mortality. Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Leukocyte Reduction Procedures. Logistic Models. Lung Diseases / epidemiology. Lung Diseases / etiology. Lung Diseases / mortality. Male. Multivariate Analysis. Nervous System Diseases / epidemiology. Nervous System Diseases / etiology. Nervous System Diseases / mortality. Tennessee / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15547931.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


77. Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW: Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia; 2010 Aug;24(8):1462-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
  • Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT).
  • However, in contrast with the usual early recurrence of leukemia, relapses were delayed up to 3 years after SCT.
  • In addition, several relapses presented at unusual extramedullary sites suggesting that the immune intervention may have altered the pattern of leukemia recurrence.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Male. Risk


78. Dincaslan HU, Yavuz G, Unal E, Tacyildiz N, Ikinciogullari A, Dogu F, Guloglu D, Yuksek N, Ertem U: Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? Pediatr Hematol Oncol; 2010 Oct;27(7):503-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
  • There are limited data related to childhood hematologic malignancies.
  • The aim of the study was to evaluate soluble VEGF (sVEGF) levels in children with acute leukemia and malignant lymphoma (ML) at diagnosis and in remission.
  • The levels of serum sVEGF were measured by enzyme-linked immunosorbent assay (ELISA) in 20 children with acute leukemia, 33 children with different histopathological subtypes of ML, and 20 healthy controls.
  • The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in acute myeloid leukemia (AML) group (P = .018).
  • The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with acute lymphoblastic leukemia (ALL) (P = .002).
  • The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood malignancies at diagnosis and in remission.
  • In acute leukemia and ML patients, VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) angiogenesis and lymphoid tissue lymphangiogenesis.
  • [MeSH-major] Hodgkin Disease / blood. Leukemia, Myeloid, Acute / blood. Lymphoma, Non-Hodgkin / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Vascular Endothelial Growth Factors / blood
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Remission Induction. Sensitivity and Specificity. Solubility

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677920.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


79. Pritchard MT, Butow PN, Stevens MM, Duley JA: Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol; 2006 Dec;28(12):816-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review.
  • Significant numbers of children and adolescents with acute lymphoblastic leukemia (ALL) do not adequately adhere to their treatment regimen.
  • [MeSH-major] Patient Compliance. Patient Education as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Secondary Prevention

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164651.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


80. Faganel Kotnik B, Dolzan V, Grabnar I, Jazbec J: Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma; 2010 Apr;51(4):724-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Membrane Transport Proteins / genetics. Methotrexate / adverse effects. Methotrexate / blood. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Drug-Related Side Effects and Adverse Reactions / genetics. Female. Genetic Predisposition to Disease. Humans. Male. Osmolar Concentration. Prognosis. Reduced Folate Carrier Protein. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141435.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ: CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia; 2007 Jun;21(6):1249-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
  • The role of CXCL12 in the bone marrow (BM) homing and growth of B-cell progenitor acute lymphoblastic leukemia (ALL) has been established.
  • We used mouse models of human childhood and murine leukemia and specific peptide and small molecule CXCR4 antagonists to examine the importance of CXCL12/CXCR4 in the development of leukemia in vivo.
  • Extended administration of CXCR4 antagonists to mice with leukemia resulted in a reduction in the number of leukemic cells in the PB and spleens of animals compared to control treated animals in three of the five cases tested.
  • [MeSH-major] Chemotaxis / drug effects. Neoplastic Cells, Circulating / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, CXCR4 / antagonists & inhibitors
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Blood. Chemokine CXCL12. Chemokines, CXC / antagonists & inhibitors. Child. Child, Preschool. Disease Models, Animal. Drug Interactions. Female. Graft Survival / drug effects. Humans. Infant. Male. Mice. Neoplasm Transplantation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Spleen. Stromal Cells. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410186.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Receptors, CXCR4
  •  go-up   go-down


82. Pelissari DM, Barbieri FE, Wünsch Filho V: Magnetic fields and acute lymphoblastic leukemia in children: a systematic review of case-control studies. Cad Saude Publica; 2009;25 Suppl 3:S441-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic fields and acute lymphoblastic leukemia in children: a systematic review of case-control studies.
  • Leukemia incidence in children has increased worldwide in recent decades, particularly due to the rise in acute lymphoblastic leukemia.
  • Studies have associated exposure to non-ionizing radiation generated by low frequency magnetic fields with childhood leukemia.
  • An association may exist between exposure to low frequency magnetic fields and acute lymphoblastic leukemia in children, but this association is weak, preventing the observation of consistency in the findings.
  • Future studies from a wider range of geographic regions should focus on the analysis of acute lymphoblastic leukemia, which is the subtype with the greatest impact on the increasing overall incidence of childhood leukemia.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Environmental Exposure / adverse effects. Leukemia, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Case-Control Studies. Child. Humans. Incidence. Odds Ratio. Radiation Dosage. Risk Factors


83. Harper JD, Shah SK, Baldwin DD, Moorhead JD: Laparoscopic nephrectomy for pediatric giant hydronephrosis. Urology; 2007 Jul;70(1):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic nephrectomy for pediatric giant hydronephrosis.
  • OBJECTIVES: To describe our experience with pediatric laparoscopic nephrectomy (LN) and laparoscopic nephroureterectomy (LNU) for giant hydronephrosis.
  • METHODS: A retrospective review was conducted of all pediatric patients undergoing a transperitoneal LN or LNU.
  • CONCLUSIONS: Although pediatric LN and LNU for giant hydronephrosis present unique challenges owing to the large renal volume in a small abdominal cavity, these procedures can be safely performed with careful attention to the altered anatomic relationships.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656227.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Singer JS, Ettenger RB, Gore JL, Gritsch HA, Rajfer J, Rosenthal JT, Schulam P: Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation. Am J Transplant; 2005 Oct;5(10):2514-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation.
  • Despite reports demonstrating the safety of laparoscopic donor nephrectomy (LDN) for pediatric recipients of renal transplants, recent evidence has challenged using LDN for recipients 5 years of age or younger.
  • We retrospectively reviewed the records of all pediatric recipients of living donor renal transplants from September 2000 through August 2004.
  • Outcomes of interest included operative complications, postoperative renal function, the incidence of delayed graft function or episodes of acute rejection and long-term graft function.
  • Rates of delayed graft function and acute rejection did not differ between groups.
  • At our center, pediatric LDN recipients have graft outcomes comparable to those of ODN recipients.
  • At experienced centers, we recommend continued use of LDN for pediatric recipients of all ages.
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Creatinine / blood. Creatinine / urine. Female. Graft Rejection. Graft Survival. Humans. Kidney / pathology. Living Donors. Male. Nephrectomy / methods. Renal Artery. Retrospective Studies. Time Factors. Tissue and Organ Harvesting / methods. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162202.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


85. Somers GR, Smith CR, Perrin DG, Wilson GJ, Taylor GP: Sudden unexpected death in infancy and childhood due to undiagnosed neoplasia: an autopsy study. Am J Forensic Med Pathol; 2006 Mar;27(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden unexpected death in infancy and childhood due to undiagnosed neoplasia: an autopsy study.
  • Sudden unexpected death due to clinically undiagnosed neoplasia in infancy and childhood (SUDNIC) is a rare phenomenon, with only small numbers of cases reported in the literature.
  • Diagnoses included 2 cases of acute leukemia (1 myelogenous, 1 lymphoblastic), 2 cases of mediastinal lymphoblastic lymphoma (pre-T cell type), 1 papillary fibroelastoma of the mitral valve prolapsing into and totally occluding the left anterior descending coronary artery, 1 medulloblastoma, 1 Wilms tumor associated with fatal intraperitoneal hemorrhage, and 1 widely disseminated gastric carcinoma.
  • These cases demonstrate that infants and children may have minimal or no symptoms in the presence of significant disease and highlight the need for a thorough autopsy examination in cases of sudden unexpected death in infancy and childhood.
  • [MeSH-minor] Adolescent. Canada / epidemiology. Child. Child, Preschool. Female. Forensic Medicine. Humans. Incidence. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501353.001).
  • [ISSN] 0195-7910
  • [Journal-full-title] The American journal of forensic medicine and pathology
  • [ISO-abbreviation] Am J Forensic Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R, den Boer ML: Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):313-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.
  • To identify miRNAs relevant to pediatric acute lymphoblastic leukemia (ALL), we cloned 105 known and 8 new miRNA genes expressed in patients' leukemia cells.
  • Eight miRNAs were differentially expressed between MLL and non-MLL precursor B-ALL cases (P<0.05).
  • Most remarkably, miR-708 was 250- up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001<P<0.01), whereas the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001).
  • The expression did not correlate with the maturation status of leukemia cells based on immunoglobulin and T-cell receptor rearrangements, immunophenotype or MLL-fusion partner.
  • [MeSH-major] MicroRNAs / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Neoplasm / genetics
  • [MeSH-minor] Cloning, Molecular. Gene Expression Regulation, Neoplastic. Humans. Infant. Infant, Newborn. Myeloid-Lymphoid Leukemia Protein / genetics


87. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML: Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol; 2009 Jul;7(7):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited.
  • Hyperglycemia has been described as a common event occurring during acute lymphocytic leukemia chemotherapy.
  • Our goal was to compare clinical and laboratory findings between hyperglycemic episodes occurring during childhood acute lymphocytic leukemia induction chemotherapy.
  • There were no differences in clinical or laboratory variables among groups, although the majority of episodes occurred in pubescents, regardless of the type of glucocorticoid employed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Glucocorticoids / adverse effects. Hyperglycemia / chemically induced. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Amylases / blood. Blood Glucose / metabolism. Body Mass Index. Child. Child, Preschool. Female. Humans. Infant. Male. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701154.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; EC 3.2.1.- / Amylases
  •  go-up   go-down


88. Martin FT, O'Sullivan JB, Regan PJ, McCann J, Kelly JL: Hydrocolloid dressing in pediatric burns may decrease operative intervention rates. J Pediatr Surg; 2010 Mar;45(3):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocolloid dressing in pediatric burns may decrease operative intervention rates.
  • INTRODUCTION: Partial-thickness scalds are the most common pediatric burn injury, and primary management consists of wound dressings to optimize the environment for reepithelialization.
  • AIM: The aim of the study was to retrospectively analyze pediatric burns in a single tertiary referral center over a 10-year period comparing the impact of Jelonet and DuoDERM dressings relative to operative intervention rates.
  • METHODS: All pediatric burns admitted between 1997 and 2007 were identified using the Hospital Inpatient Enquiry system.
  • Acute, partial-thickness burns in patients younger than 15 years were analyzed according to dressing type applied (Jelonet or DuoDERM).
  • RESULTS: Two hundred forty-eight pediatric burns were analyzed between 1997 and 2007.
  • CONCLUSION: Observational evidence suggests that DuoDERM leads to less operative intervention and should be preferentially used in pediatric burns.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay. Male. Pain Measurement. Probability. Retrospective Studies. Risk Assessment. Treatment Outcome. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Burns.
  • Hazardous Substances Data Bank. PETROLATUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223327.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / jelonet; 8009-03-8 / Petrolatum
  •  go-up   go-down


89. Harley NH, Robbins ES: Radon and leukemia in the Danish study: another source of dose. Health Phys; 2009 Oct;97(4):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radon and leukemia in the Danish study: another source of dose.
  • An epidemiologic study of childhood leukemia in Denmark (2,400 cases; 6,697 controls) from 1968 to 1994 suggested a weak, but statistically significant, association of residential radon exposure and acute childhood lymphoblastic leukemia (ALL).
  • The relatively high dose estimate to lymphocytes circulating through the BE, potential precursor cells for ALL, provides a dose pathway for an association.
  • [MeSH-major] Leukemia / etiology. Neoplasms, Radiation-Induced / epidemiology. Radon / analysis
  • [MeSH-minor] Air Pollutants, Radioactive. Bone Marrow / radiation effects. Bronchi / radiation effects. Child. Epithelium / radiation effects. Humans. Lung / radiation effects. Lymph Nodes / radiation effects. Lymphocytes / radiation effects. Phagocytosis / radiation effects. Radiometry. Risk

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Radon.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741363.001).
  • [ISSN] 1538-5159
  • [Journal-full-title] Health physics
  • [ISO-abbreviation] Health Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Radioactive; Q74S4N8N1G / Radon
  •  go-up   go-down


90. Wu S, Gessner R, Taube T, Korte A, von Stackelberg A, Kirchner R, Henze G, Seeger K: Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse. J Pediatr Hematol Oncol; 2006 Apr;28(4):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse.
  • In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).
  • [MeSH-major] Bone Marrow / pathology. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, CXCR4 / genetics. Receptors, Chemokine / genetics
  • [MeSH-minor] Child. DNA Primers. Humans. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Receptors, CXCR3. Recurrence. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679918.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR3 protein, human; 0 / DNA Primers; 0 / Interleukin-8; 0 / RNA, Neoplasm; 0 / Receptors, CXCR3; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


91. Schipper RG, van den Heuvel LP, Verhofstad AA, De Abreu RA: Polyamines and DNA methylation in childhood leukaemia. Biochem Soc Trans; 2007 Apr;35(Pt 2):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyamines and DNA methylation in childhood leukaemia.
  • In previous studies we showed that 6-MP (6-mercaptopurine) as well as MTX (methotrexate), well-known drugs in the treatment of acute lymphoblastic leukaemia, inhibit DNA methylation and induce apoptosis in malignant blood cells.
  • [MeSH-major] DNA Methylation. Polyamines / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Child. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Humans. S-Adenosylmethionine / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371272.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Polyamines; 7LP2MPO46S / S-Adenosylmethionine
  •  go-up   go-down


92. Meyer S, White DJ, Will AM, Eden T, Sim A, Brown R, Strathdee G: No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Br J Haematol; 2006 Jul;134(1):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.
  • Combined bisulphite restriction analysis for methylation of FANCF, FANCB and NBS1 was used to investigate 81 sporadic acute childhood leukaemias.
  • This does not exclude very low levels of FANCF, FANCB or NBS1 methylation, but suggests other factors are responsible for chemo-sensitivity and chromosomal instability in sporadic childhood leukaemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. Fanconi Anemia Complementation Group Proteins / genetics. Leukemia / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosomal Instability. CpG Islands. DNA Methylation. Fanconi Anemia Complementation Group F Protein / genetics. Genes, Neoplasm / genetics. Humans. Infant. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Nijmegen breakage syndrome.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803569.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Fanconi Anemia Complementation Group F Protein; 0 / Fanconi Anemia Complementation Group Proteins; 0 / NBN protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


93. Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C: Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer; 2010 Jul 1;54(7):934-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
  • BACKGROUND: Osteonecrosis is a well-recognised complication of current childhood acute lymphoblastic leukaemia (ALL) therapy.
  • CONCLUSION: Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Diphosphonates / therapeutic use. Osteonecrosis / chemically induced. Osteonecrosis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adrenal Cortex Hormones / therapeutic use. Alendronate / administration & dosage. Calcium / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infusions, Intravenous. Male. Pain / drug therapy. Pain / etiology. Radiotherapy. Risk Factors. Vitamin D / therapeutic use

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20127847.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Diphosphonates; 1406-16-2 / Vitamin D; OYY3447OMC / pamidronate; SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


94. Weinberg ST, Kaiser AB, Waitman LR, Webb T: Experience with ConsultWiz--the simultaneous electronic notification, documentation, and tracking of inpatient consult requests. AMIA Annu Symp Proc; 2006;:1139
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Piloted in the Dept of Medicine in Spring, 2005, ConsultWiz was expanded to include all remaining adult services in July, 2005 and all pediatric consult services in October, 2005.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Healthc Qual. 2003 Jan-Feb;25(1):27-35 [12879628.001]
  • (PMID = 17238758.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1839338
  •  go-up   go-down


95. Korenkov AI, Imhof HG, Brandner S, Taub E, Huguenin PU, Gaab MR, Yonekawa Y: Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. J Neurooncol; 2005 Sep;74(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature.
  • We report a case of meningioma diagnosed 23 years after high-dose cranial and whole-body irradiation for the treatment of acute lymphocytic leukemia (ALL).
  • Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.
  • [MeSH-major] Cataract / etiology. Cranial Irradiation / adverse effects. Growth Disorders / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


96. Irving JA, Minto L, Bailey S, Hall AG: Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res; 2005 Nov 1;65(21):9712-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course.
  • Glucocorticoids are pivotal in the treatment of children with acute lymphoblastic leukemia (ALL) and have significant antileukemic effects in the majority of children.
  • There was no evidence of a remaining wild-type allele.
  • [MeSH-major] Loss of Heterozygosity. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Glucocorticoid / genetics
  • [MeSH-minor] Alleles. Bone Marrow / pathology. Cell Line, Tumor. Child. Child, Preschool. Cohort Studies. Exons. Gene Deletion. Humans. Microsatellite Repeats / genetics. Prednisolone / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266991.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


97. Goyal S, Yue NJ, Millevoi R, Kagan E, Haffty B, Narra V: Improvement in dose homogeneity with electronic tissue compensation over IMRT and conventional RT in whole brain radiotherapy. Radiother Oncol; 2008 Aug;88(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Ten patients (6 adult, 4 pediatric) who were treated at our institution were selected for this study.
  • At our institution, ECOMP is being used in all pediatric patients or select adult patients with a long life expectancy requiring cranial radiotherapy.
  • [MeSH-minor] Adult. Child. Humans. Radiation Dosage. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362037.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


98. Berbel Tornero O, Ortega García JA, Ferrís i Tortajada J, García Castell J, Donat i Colomer J, Soldin OP, Fuster Soler JL: [Neonatal tumours and congenital malformations]. An Pediatr (Barc); 2008 Jun;68(6):589-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The association between pediatric cancer and congenital abnormalities is well known but, there is no exclusive data on the neonatal period and the underlying etiopathogenic mechanisms are unknown.
  • RESULTS: 72 neonatal tumours were identified (2.8% of all pediatric cancers diagnosed in our hospital) and in 15 cases (20.8%) there was some associated malformation, disease or syndrome.
  • f) acute leukaemia in one patient with Down syndrome and congenital heart disease;.
  • The publications included the tumours diagnosed in different pediatric periods and without unified criteria to classify the congenital abnormalities.
  • CONCLUSIONS: Neonatal tumours are more often associated to congenital abnormalities than other pediatric cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1674-9 [8082067.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):639-44 [8470665.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] In Vivo. 1990 Sep-Oct;4(5):327-35 [2133106.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):1025-8 [2069840.001]
  • [Cites] Arch Dis Child. 1987 Jan;62(1):19-23 [3813632.001]
  • [Cites] Cancer Detect Prev. 1986;9(1-2):1-7 [3731185.001]
  • [Cites] Pediatr Pathol. 1985;3(2-4):165-216 [3879355.001]
  • [Cites] Cancer. 2005 May 1;103(9):1939-48 [15770693.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):74-84 [15264275.001]
  • [Cites] Pediatr Surg Int. 2003 Sep;19(7):509-19 [14523568.001]
  • [Cites] Pediatr Surg Int. 2002 Sep;18(5-6):306-9 [12415344.001]
  • [Cites] Curr Oncol Rep. 2000 May;2(3):234-41 [11122848.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):255-67 [16197716.001]
  • (PMID = 18559198.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR020359
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Other-IDs] NLM/ NIHMS459185; NLM/ PMC3635533
  •  go-up   go-down


99. Li CK: [Induction chemotherapy in childhood acute lymphoblastic leukemia: the association between the intensity of therapy and cure]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):321-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy in childhood acute lymphoblastic leukemia: the association between the intensity of therapy and cure].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods
  • [MeSH-minor] Child. Child, Preschool. Drug Therapy. Humans. Survival Analysis. Treatment Outcome


100. Martin BT, Williamson BD, Edwards N, Teng AY: Parental symptom report and periodic limb movements of sleep in children. J Clin Sleep Med; 2008 Feb 15;4(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At their initial sleep clinic visit, parents had been asked whether their child was restless or moved their legs excessively during sleep.
  • Their response to these questions was compared to the child's PLMS index (number of periodic limb movements per hour) during a full PSG.
  • Asking parents about whether their child kicks their legs excessively in sleep had sensitivity 50%, specificity 51%, positive predictive value (PPV) 10%, negative predictive value (NPV) 90% and positive likelihood ratio (LR+) 1.02 when compared to objective analysis.
  • Asking parents about whether their child is restless in sleep had sensitivity 70%, specificity 26%, PPV 9%, NPV 89% and LR+ 0.95.
  • CONCLUSIONS: Asking parents about their child's symptoms is not an accurate predictor of raised PLMS index.
  • We recommend that leg electromyography be used in all pediatric sleep studies to record PLMS.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Male. New South Wales. Parents. Referral and Consultation / statistics & numerical data. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 1995;245(1):8-10 [7786913.001]
  • [Cites] Neuropsychopharmacology. 1996 Jun;14(6):437-42 [8726754.001]
  • [Cites] Mov Disord. 1997 Jan;12(1):61-5 [8990055.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):588-94 [9881529.001]
  • [Cites] Neurology. 1999 Mar 23;52(5):932-7 [10102408.001]
  • [Cites] Sleep. 1999 May 1;22(3):297-300 [10341379.001]
  • [Cites] Dev Med Child Neurol. 2004 Nov;46(11):765-70 [15540638.001]
  • [Cites] Ann Neurol. 2004 Dec;56(6):803-7 [15505786.001]
  • [Cites] Pediatr Pulmonol. 2005 Jul;40(1):22-30 [15858805.001]
  • [Cites] Sleep Med. 2005 Jul;6(4):325-32 [15978516.001]
  • [Cites] Sleep. 2005 Aug 1;28(8):1007-13 [16218085.001]
  • [Cites] Sleep Med. 2005 Nov;6(6):507-13 [16271695.001]
  • [Cites] Paediatr Respir Rev. 2006;7 Suppl 1:S55-7 [16798596.001]
  • [Cites] Sleep. 2006 Sep;29(9):1183-7 [17040005.001]
  • [Cites] Mov Disord. 1999 Nov;14(6):1000-7 [10584676.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):502-4 [10668725.001]
  • [Cites] Sleep. 2001 May 1;24(3):313-20 [11322714.001]
  • [Cites] Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10 [11422885.001]
  • [Cites] Sleep. 2002 Mar 15;25(2):213-8 [11902431.001]
  • [Cites] J Psychosom Res. 2002 Jul;53(1):547-54 [12127170.001]
  • [Cites] J Sleep Res. 2003 Mar;12(1):73-81 [12603789.001]
  • [Cites] Sleep. 2003 Jun 15;26(4):480-3 [12841376.001]
  • [Cites] Sleep. 2003 Sep15;26(6):735-8 [14572128.001]
  • [Cites] Sleep Med. 2003 Mar;4(2):101-19 [14592341.001]
  • [Cites] Sleep. 2004 Mar 15;27(2):313-5 [15124728.001]
  • [Cites] Ann Neurol. 1980 Oct;8(4):416-21 [7436384.001]
  • [Cites] Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1235-9 [1443877.001]
  • (PMID = 18350964.001).
  • [ISSN] 1550-9389
  • [Journal-full-title] Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
  • [ISO-abbreviation] J Clin Sleep Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2276827
  •  go-up   go-down






Advertisement